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Material Biocompatibility and Applications in Metabolic Monitoring 
Michail Kastellorizios, PhD 
University of Connecticut, 2015 
The present dissertation focuses and expands on the optimization and application of poly(lactic-
co-glycolic acid) (PLGA)/polyvinyl alcohol (PVA) composite coatings and initiates metabolic 
studies in small animals to identify novel biomarkers to be utilized in exhaustion prediction. The 
composites are used to coat implantable biosensors and improve their biocompatibility. The 
objectives of the work are: i) investigate species differences related to the foreign body reaction 
(FBR) between small and large animals; ii) develop composite coatings to prevent the FBR in 
large animals; iii) develop composites loaded with combinations of dexamethasone, vascular 
endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) to promote 
angiogenesis around implanted biosensors; and iv) apply multi-analyte monitoring to exhaustion 
prediction. 
The onset and severity of fibrosis was identified as a key difference between minipigs and rats, 
with minipigs demonstrating earlier onset and more severe chronic inflammation. In order to 
counter this, dexamethasone release must be continuous, with no lag phase. The effective 
dexamethasone dosing regime was 100 μg during the first day and 10 μg/day thereafter. 
A novel method for the preparation of microspheres containing insoluble drugs was developed to 
achieve homogeneous drug distribution, high loading and low burst release. Dexamethasone 
microspheres prepared by this method were utilized in microsphere/hydrogel composite coatings 
which successfully prevented FBR in a large animal model for a period of one month. 
Michail Kastellorizios – University of Connecticut, 2015 
Combinations of dexamethasone, VEGF and PDGF were investigated for the first time to prevent 
FBR and promote angiogenesis. It was determined that VEGF has to be delivered at higher doses 
than PDGF and an increase in dexamethasone must be accompanied by proportional increase in 
growth factors.  
An array of biomarkers that can be used in exhaustion prediction was successfully identified, with 
prediction times ranging from 10 to 20 minutes in normal as well as type 1 diabetic rats. It was 
discovered that multi-analyte biomarkers based on glucose and lactate are far more responsive in 
the subcutaneous tissue (an implantation-friendly compartment) than in the blood. 
In conclusion, the outcomes of this work contribute to the advancement biomaterials, as well as 
applications in exercise physiology. 
Material Biocompatibility and Applications in Metabolic Monitoring 
 
Michail Kastellorizios 
 
B.Pharm., University of Patras, 2008 
M.Sc., University of Patras, 2010 
 
 
 
 
 
A Dissertation 
Submitted in Partial Fulfillment of the 
Requirements for the Degree of  
Doctor of Philosophy 
at the 
University of Connecticut  
2015 

iii 
 
Acknowledgements 
I would like to express my sincere appreciation to my advisor Dr. Diane J. Burgess. You are the 
best mentor that a new scientist can hope for, and I will always be grateful for the encouragement 
I received to pursue my research interests. Your advice has proven invaluable for my research as 
well as my career. Thanks to your mentorship I learned the importance of multi-disciplinary 
approaches, critical thinking and hard work, and developed professional, leadership, and team-
building skills. Thank you for your patience and the hard work that you dedicated to me, and I 
sincerely hope that our professional and personal relationship will last and grow. 
A special thanks to Dr. Fotios Papadimitrakopoulos, my associate advisor, for his continuing 
support, advice, and his efforts to sustain a multi-disciplinary project which I was fortunate to be 
part of. I am also very thankful to Dr. Xiuling Lu, my associate advisor, for her advice and the 
time she dedicated to my work. 
I am deeply thankful to the Pharmaceutics faculty members Dr. Michael Pikal, Dr. Devendra 
Kalonia, Dr. Robin Bogner, and Dr. Bodhi Chaudhuri for the exceptional coursework and scientific 
input, Dr. Faquir Jain for his collaboration and to Dr. David Grant for allowing me to use 
instruments in his laboratory. I am grateful for the immense help I received from the School of 
Pharmacy administrative personnel, especially from Ms. Leslie Lebel, Mr. Mark Armati, Ms. 
Laura Burnett, Ms. Kathleen Koji, Ms. Mina Boone and Ms. Jacqueline Maliga. 
I would like to thank all past and present project collaborators and lab members, especially Dr. 
Sagar Vaddiraju, Dr. Yan Wang, Ms. Namita Tipnis, Mr. Bing Gu, Dr. Jie Shen, Dr. Robert Croce, 
Mr. Allen Legassey, Mr. Nanda Kommineni, Ms. Claire Price, Dr. Jacqueline Morais, Dr. Sudhir 
Verma, Dr. Archana Rawat, Dr. Xiaoming Xu, Dr. Sumit Kumar, Dr. Nitin Swarnakar, Mr. 
Antonio Costa, Mr. Minsung Suh, Mr. Rajan Jog, Ms. Janki Andhariya, Ms. Carmen Zhang, and 
everyone else who offered me their help and friendship. 
iv 
 
This work would not have been possible without the help and support from UConn’s Animal Care 
Services, the Institutional Animal Care and Use Committee and the attending veterinarian Dr. 
Cecile Baccanale who helped me ensure that all animal studies were performed with utmost respect 
to animal life. A very special thanks to Ms. Janet Trombley who went out of her way time and 
again to help me with the care, enrichment and experimental aspects of the minipig studies 
presented here. I will never forget your help. 
I would like to acknowledge the financial support I received from the United States Department 
of Defense for my research projects and the University of Connecticut for the assistantships and 
tuition waivers. 
Lastly, I would never have reached this point without the love and support from my parents, 
Georgios Kastellorizios and Theodora Lakata, my brother Nikolaos Kastellorizios, my extended 
family and friends, and of course my spiritual guide and inspiration Shri Mataji Nirmala Devi. 
  
v 
 
Table of Contents 
Approval Page ii 
Acknowledgements iii 
Chapter 1 
Introduction 
1.1.  Background 2 
1.2.  Objectives 4 
1.3.  References 5 
Chapter 2 
‘Prevention of Foreign Body Reaction in a Pre-Clinical Large Animal Model’ 
Abstract 8 
2.1. Introduction 9 
2.2. Materials and Methods 10 
2.2.1. Materials 10 
2.2.2. PLGA microsphere preparation 11 
2.2.3. Preparation of implants 11 
2.2.4. PLGA microsphere characterization 12 
2.2.5. In vivo pharmacodynamics study 13 
2.2.6. Histological evaluation 13 
2.3. Results 14 
2.3.1. Microsphere characterization 14 
2.3.2. FBR to implants with no dexamethasone 14 
2.3.3. Effect of total dexamethasone dose 14 
2.3.4. Effect of PLGA molecular weight 15 
2.4. Discussion 16 
2.5. Conclusions 19 
2.6. References 19 
Chapter 3 
‘Development of Dexamethasone-Loaded PLGA Microspheres for Long-Term 
Prevention of the Foreign Body Reaction in Gottingen Minipigs’ 
Abstract 24 
3.1. Introduction 25 
3.2. Materials and Methods 26 
3.2.1. Materials 26 
3.2.2. Microsphere preparation 27 
3.2.3. Optimization of microsphere preparation method 27 
3.2.4. Characterization of PLGA microspheres 28 
3.2.5. Preparation of composite coatings 28 
3.2.6. In vitro release testing of the composite coatings 29 
3.2.7. In vivo study 29 
3.2.8. Statistical analysis 30 
3.3. Results 30 
3.3.1. Optimization of microsphere preparation method 30 
3.3.2. Microsphere characterization 30 
3.3.3. In vitro release 31 
3.3.4. In vivo evaluation of the anti-FBR properties of the composite coatings 31 
vi 
 
3.4. Discussion 32 
3.5. Conclusions 34 
3.6. References 34 
Chapter 4 
‘Delivery of Dexamethasone, VEGF, and PDGF to Promote Angiogenesis and Prevent 
the Foreign Body Reaction in Subcutaneous Implants’ 
Abstract 37 
4.1. Introduction 38 
4.2. Materials and Methods 40 
4.2.1. Materials 40 
4.2.2. Formulation of protein microspheres 40 
4.2.3. Formulation of dexamethasone microspheres 41 
4.2.4. Microsphere characterization 41 
4.2.5. Fabrication of composites 42 
4.2.6. Investigation of VEGF-to-PDGF ratio 42 
4.2.7. Investigation of dexamethasone-to-growth factors ratio 43 
4.3. Results 43 
4.3.1. Microsphere preparation and characterization 43 
4.3.2. VEGF-to-PDGF ratio 44 
4.3.3. Adjustment of dexamethasone dose 44 
4.4. Discussion 45 
4.5. Conclusions 47 
4.6. References 48 
Chapter 5 
‘Continuous Metabolic Monitoring Based on Multi-Analyte Biomarkers to Predict 
Exhaustion’ 
Abstract 51 
5.1. Introduction 52 
5.2. Materials and Methods 53 
5.2.1. Animal models 53 
5.2.2. Microdialysis 54 
5.2.3. Exercise experiments 54 
5.2.4. Analyte quantification 54 
5.2.5. Data analysis 55 
5.3. Results  55 
5.3.1. Choice of analytes to be monitored 55 
5.3.2. Glucose and lactate changes during intense exercise 55 
5.3.3. Multi-analyte biomarker identification 57 
5.3.4. Multi-analyte biomarkers for prediction of exhaustion 57 
5.4. Discussion 58 
5.5. References 59 
Chapter 6 
Conclusions and Future Studies 
6.1. Summary and conclusions 62 
6.2. Future Studies 65 
Appendix I - Figures 
vii 
 
Figure 2.1. 
Histological evaluation of the foreign body reaction to control (no 
dexamethasone) implants. Star denotes implant location. Connective 
tissue is stained pink, collagen fibers light pink and inflammatory cells 
purple (H&E staining). a: day 1; b: day 3; c: day 7; d: day 14; e: day 21; 
f: day 30 post-implantation (n=3). Scale bar: 500 μm. 
68 
Figure 2.2. 
Comparison of FBR in rats and minipigs 7 days post-implantation. Star 
denotes implant location. Connective tissue is stained pink, collagen 
fibers light pink and inflammatory cells purple (H&E staining). Green 
arrow: collagen fibers; black arrow: fibroblasts. Rat image taken from 
Patil et. al.43 Fibroblasts were identified based on the cell morphology. 
Active fibroblasts have oval shape with spherical nucleus and are 
characteristically positioned in-between collagen fibers which they 
produce. 
69 
Figure 2.3. 
Histological evaluation of the foreign body reaction to dexamethasone-
releasing implants R, R9, R11 and R150 on days 3, 7, 14, 21, and 30 
post-implantation. Star denotes implant location. Connective tissue is 
stained pink, collagen fibers light pink and inflammatory cells purple 
(H&E staining) (n=3). Scale bar: 500 μm. 
70 
Figure 2.4. 
Histological evaluation of the foreign body reaction to dexamethasone-
releasing implants R2W. Star denotes implant location. Connective 
tissue is stained pink, collagen fibers light pink and inflammatory cells 
purple (H&E staining). a: day 1; b: day 3; c: day 7; d: day 11; e: day 14; 
f: day 21 post-implantation (n=4). Scale bar: 500 μm. 
71 
Figure 3.1. 
Polarized light microscopy (PLM) images of two emulsions during 
PLGA microsphere preparation. Drug crystals appear as bright spots in 
the PLM images. (a) Example of non-optimized process, with 
dexamethasone crystals formed outside the polymer phase (polymer 
droplets not visible due to their inability to polarize light). (b) 
Optimized formulation with dexamethasone precipitated inside the 
polymer phase. Magnification: 10X, scale bar: 500 μm. 
72 
Figure 3.2. 
PLM images of negative control formulation (left) with poor drug 
distribution in the polymer matrix and optimized formulation (right). 
Dexamethasone crystals appear bright under PLM while the polymer is 
transparent. Magnification: 40X, scale bars: 10 μm. 
73 
Figure 3.3. 
Cumulative in vitro release of dexamethasone from optimized PLGA 
microspheres embedded in a PVA hydrogels. All values are average ± 
SD (n = 3). Linear regression was applied from day 4 to day 45. 
74 
Figure 3.4. 
Histological evaluation of the foreign body reaction to control (no 
dexamethasone) implants. Star denotes implant location. Connective 
tissue is stained pink, collagen fibers light pink and inflammatory cells 
purple (H&E staining). (a) day 3; (b) day 7; (c) day 14; (d) day 21; (e) 
day 30 post-implantation. Magnification: 10X, scale bar: 500 μm. 
75 
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Figure 3.5. 
Histological evaluation of the foreign body reaction to coated silicon 
chips with the optimized PLGA microsphere formulation. Star denotes 
implant location. Connective tissue is stained pink, collagen fibers light 
pink and inflammatory cells purple (H&E staining). (a) day 3; (b) day 
7; (c) day 14; (d) day 21; (e) day 30 post-implantation. Magnification: 
10X, scale bar: 500 μm. 
76 
Figure 3.6. 
Histological evaluation of FBR to composites with the optimized 
PLGA microsphere formulation with no silicon chips at their core. Star 
denotes implant location. Connective tissue is stained pink, collagen 
fibers light pink and inflammatory cells purple (H&E staining). (a) day 
3; (b) day 7; (c) day 14; (d) day 21; (e) day 30 post-implantation. 
Magnification: 10X, scale bar: 500 μm. 
77 
Figure 4.1. 
Schematic representation of the single-vessel microsphere preparation 
process. 78 
Figure 4.2. 
a) Confocal microscopy images of protein microsphere formulations 
with (right) and without (left) NaCl in the outer water phase; b) drug 
loading, encapsulation efficiency, and % burst release of the 
formulations with and without NaCl (mean ± SD, n=3). 
79 
Figure 4.3. 
Anti-sma-stained tissue sections showing normal tissue (N) and 
composites C, D, DV, DVP, and D2VPa. Star denotes implant location. 
Magnification: 20x. Scale bar: 150 μm. 
80 
Figure 4.4. 
H&E-stained tissue sections of composites D, DV, D2VPb, and 2D2VP 
at different time points following implantation. Star denotes implant 
location. Magnification: 10x. Scale bar: 500 μm. 
81 
Figure 4.5. 
Anti-sma-stained tissue sections of composites D, DV, D2VPb, and 
2D2VP at different time points following implantation. Star denotes 
implant location. Magnification: 10x. Scale bar: 500 μm. 
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Figure 4.6. 
Anti-sma-stained tissue sections of composites D, DV, D2VPb, and 
2D2VP at different time points following implantation. Star denotes 
implant location. Magnification: 140x. Scale bar: 100 μm. 
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Figure 4.7. 
Capillary density within a 200 μm distance from the implant surface for 
composites D, DV, D2VPb and 2D2VP (mean ± SD, n=3). 84 
Figure 5.1. 
Effect of light and intense exercise on oxygen and carbon dioxide levels 
in the blood and subcutaneous tissue. Areas shaded blue and green 
indicate light and intense exercise, respectively, and unshaded areas 
indicate periods of inactivity (rest or recovery). The top panel displays 
oxygen level changes and the bottom panel carbon dioxide changes in 
the dialysate. Arrows indicate y axis. Oxygen levels did not respond to 
light exercise but only during intense exercise. Carbon dioxide levels 
responded to both light and intense exercise, but showed highly 
unstable readings. 
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Figure 5.2. 
Effect of intense exercise and exhaustion on glucose and lactate levels 
in the blood and subcutaneous tissue. Areas shaded green and red 
indicate periods of intense exercise and exhaustion, respectively. 
Exhaustion was defined as the time when the animal could not keep up 
with the exercise and the running speed needed to be adjusted. 
Unshaded areas indicate periods of inactivity (rest or recovery). Arrows 
indicate y axis. Top panels show glucose and lower panels show lactate 
changes in the dialysate. Panel a shows representative graph from a 
normal rat and panel b from a diabetic rat. Changes in analyte trends 
precede the onset of exhaustion (red ovals). These are clearer in lactate 
trends for both normal and diabetic rats. 
86 
Figure 5.3. 
Slope changes for various biomarker combinations of glucose (GLU) 
and lactate (LAC). All ratios are molar and the percentile changes are 
calculated based on the baseline measurements before the 
commencement of the exercise. The first peak represents metabolic 
changes from rest to activity and the second peak metabolic changes 
that precede exhaustion (predictive). Panel a shows representative 
results from a normal rat and panel b from a diabetic rat. 
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Figure 5.4a. 
Effect of intense exercise and exhaustion on the biomarker 2LAC/GLU 
(molar ratio of lactate and glucose multiplied by 2). Areas shaded green 
and red indicate periods of intense exercise and exhaustion, 
respectively. Exhaustion was defined as the time when the animal could 
not keep up with the exercise and the running speed needed to be 
adjusted. Unshaded areas indicate periods of inactivity (rest or 
recovery). Arrows indicate y axis. Red ovals indicate the exhaustion-
prediction point. The top panel shows representative results from a 
normal rat and the bottom panel from a diabetic rat. 2LAC/GLU is the 
optimum biomarker for detecting metabolic changes in the 
subcutaneous tissue predictive of imminent exhaustion. The results are 
less clear in the diabetic rat; please note that diabetic rats did not receive 
insulin treatment, and the baseline glucose was high. This likely 
interfered with the biomarkers. 
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Figure 5.4b. 
3D representation of glucose and lactate changes during intense 
exercise and exhaustion in a normal rat. This plot reveals the 
interdependence of glucose and lactate that can be extrapolated to 
evaluate the metabolic flexibility (the ability to transition from aerobic 
to anaerobic energy utilization). The peak in the graph indicates 
metabolic changes predictive of exhaustion. 
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Chapter 1 
Introduction 
  
2 
 
1.1. Background 
Diabetes mellitus1-3, obesity4-9, metabolic syndrome8, 10-15 and intense physical activity16-19 are 
a few examples of conditions whose management requires close monitoring of their progress and 
status. Typically, this takes place via monitoring of the overall physical condition of the individual 
(weight, weight fluctuations, routine blood/urine tests, etc.). In addition to routine health screening, 
monitoring of condition-specific biomarkers is essential for adequate management as well as 
prevention in high-risk populations.  For example, blood pressure and lipid content are periodically 
checked in patients with metabolic syndrome or those at risk of developing metabolic syndrome 
such as the obese. 
Glucose, the main energy source in the body, has been identified as one of the most informative 
metabolic biomarkers regardless of the metabolic condition being treated. Fasting glucose20-24 and 
the oral glucose tolerance test (OGTT)25-30 are two tests run routinely (typically on a semi-annual 
or quarterly basis) to pick up metabolic abnormalities. Diabetic patients require more frequent 
glucose monitoring (multi-daily) in order to account for pre-meal blood glucose concentrations 
when deciding the dose of insulin to be injected and/or the type and amount of food to be 
consumed. However, the aforementioned glucose tests and monitoring regimes can only give 
discreet values of glucose levels; they do not provide glucose trends (increasing or decreasing) or 
glucose fluctuations between measurements. As a result, managing the metabolic condition 
becomes a daily struggle for patients who are required to be on alert 24/7 and take important 
decisions on insulin (a very toxic drug) dosing. Accordingly, continuous glucose monitoring is 
necessary for the successful management of metabolic diseases, particularly diabetes. 
Previous research has provided competitive solutions towards the realization of a fully 
implantable metabolic biosensor regarding the four major challenges surrounding metabolic 
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monitoring: i) long-term biosensor functionality in the body; ii) sensitivity and response linearity 
of multi-analyte biosensors; iii) miniaturization and wireless communications; and iv) 
interpretation of metabolic data and identification of monitoring biomarkers. This has resulted in: 
a) subcutaneously-implanted multi-analyte biosensors with superior sensitivity and response 
linearity in rats31, 32; b) miniaturized electrical circuits and wireless communication and power 
supply platforms33; and c) composite biosensor coatings that suppress the body’s reaction to 
implanted biosensors for three months in rats34-38. 
The biosensor coatings presented here are made of poly(lactic-co-glycolic acid) (PLGA) 
microspheres embedded in a polyvinyl alcohol (PVA) hydrogel. The PVA hydrogel acts as base 
for the coating that allows glucose and other analytes to diffuse from the local microenvironment 
to the biosensor. In addition, PVA-based hydrogels have mechanical properties similar to that of 
soft tissues such as the subcutaneous tissue; this ensures that the implant will not cause tissue 
trauma. The PLGA microspheres serve as drug depots that release dexamethasone, a synthetic 
glucocorticosteroid with immunosuppressant and anti-inflammatory action. Dexamethasone was 
chosen due to its high potency that allows suppression of the foreign body response (FBR) with 
small amounts of drug, a necessity resulting from the small size of the biosensors. The PLGA 
microsphere/PVA hydrogel coatings have been tested in small animals (rats) to optimize the 
dexamethasone dose and release kinetics. Our group has successfully tested a first generation of 
semi-implantable coated glucose biosensors in rats that maintained functionality for one month. 
In addition to dexamethasone, vascular endothelial growth factor (VEGF) has been 
incorporated in the PLGA/PVA coatings to induce angiogenesis, the sprouting of blood vessels39. 
Continuous release of VEGF from the PLGA microspheres into the subcutaneous tissue 
microenvironment has offset the dexamethasone-induced ischemia observed in dexamethasone-
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only coatings. Adequate perfusion (amount of blood volume) at the biosensor microenvironment 
is essential to ensure rapid transfer of blood glucose to the subcutaneous tissue, to be quantified 
by the implanted biosensor with minimal lag time. 
1.2. Objectives 
The present dissertation focuses and expands on the optimization and application of 
poly(lactic-co-glycolic acid) (PLGA)/polyvinyl alcohol (PVA) composite coatings and initiates 
metabolic studies in small animals to identify novel biomarkers to be utilized in exhaustion 
prediction. These composites are used to coat implantable biosensors and improve their 
biocompatibility. The objectives of the work are: i) investigate species differences related to the 
foreign body reaction (FBR) between small and large animals; ii) develop composite coatings to 
prevent the FBR in large animals; iii) develop composites loaded with combinations of 
dexamethasone, vascular endothelial growth factor (VEGF) and platelet derived growth factor 
(PDGF) to promote angiogenesis around implanted biosensors; and iv) apply multi-analyte 
monitoring for exhaustion prediction. 
The work was divided into four Specific Aims: 
SA-I Prevention of the foreign body reaction in a pre-clinical large animal model: inter-species 
differences 
SA-II Development of dexamethasone-loaded PLGA microspheres for long-term prevention of 
the foreign body reaction in Gottingen minipigs 
SA-III Delivery of dexamethasone, VEGF, and PDGF to promote angiogenesis and prevent the 
foreign body reaction in subcutaneous implants 
SA-IV Continuous metabolic monitoring based on multi-analyte biomarkers to predict exhaustion 
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Chapter 2 
Prevention of Foreign Body Reaction in a Pre-Clinical Large Animal Model 
Abstract 
In this work, the foreign body reaction (FBR) to small subcutaneous implants was compared 
between small (rodent) and large (swine) animal species for the first time. Dexamethasone-
releasing poly(lactic-co-glycolic acid) microspheres/polyvinyl alcohol hydrogel composite 
coatings were adapted to prevent FBR to small, subcutaneous implants in a large animal model 
(Goettingen minipigs). The implants consisted of small silicon chips (used to mimic small medical 
devices) that were coated with the composite formulations. The stages of the FBR were compared 
with previous studies in rats (that used the same-sized implants); the onset and severity of chronic 
inflammation (collagen deposition) was identified as a key difference between the two species. In 
the absence of inflammation control, fibrosis was observed from day 7 post-implantation in 
minipigs, whereas in rats this did not occur until day 14. This is significant as swine skin is the 
most commonly used model for preclinical testing of dermal formulations. It was determined that 
for long-term prevention of the FBR (longer than 24 hours), a lag phase in dexamethasone release 
between days 1 and 10 did not affect the anti-FBR properties of the implant in rats. However, 
continuous release of dexamethasone, with no lag phase, was necessary to prevent inflammation 
in minipigs (effective dexamethasone dose was 100 μg delivered immediately after implantation 
and 10 μg/day delivered continuously thereafter). This study offers significant insight into the 
translation of anti-FBR strategies across species, and showcases the importance of tailoring the 
controlled release kinetics of the formulation to the host response. 
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2.1. Introduction 
Implantable biomaterials such as biosensors are recognized by the immune system as foreign; 
this leads to a cascade of events collectively known as the foreign body reaction (FBR)1, 2. The 
FBR consists of two main phases: an acute phase, characterized by the infiltration of inflammatory 
cells, mainly neutrophils, and a chronic phase, characterized by the presence of active fibroblasts 
(cells that deposit collagen fibers around the implant)1, 3-5. The collagen fibers will ultimately 
encapsulate the foreign body in a dense, fibrous collagen layer (fibrosis). 
The FBR has been the focus of many research studies over the past decades. Most of the early 
work in this area was related to organ rejection prevention6-8. In recent years, the emergence of 
implantable medical devices has led to the FBR being investigated to extend device lifetime9-12. In 
the case of subcutaneously implanted devices, their size, shape, mechanical properties, type of 
biomaterial, implantation duration and even method of implantation can yield a different response. 
The FBR can be minimized by using materials with mechanical properties similar to those of the 
surrounding tissue13-15, by incorporating hydrophilic coatings that prevent protein adsorption 
(biofouling)16-20 and by using biocompatible materials that do not produce toxic or irritating by-
products upon degradation21-24. However, these approaches only minimize the FBR but do not 
eliminate it altogether. The only method that has been shown to completely prevent the FBR is the 
use of local delivery of anti-inflammatory agents which prevent infiltration and further attraction 
of inflammatory cells25-32. Systemic administration of anti-inflammatory agents and immuno-
suppressants is regularly used to prevent organ rejection33-41 but it is not a desirable approach for 
medical devices and implantable biomaterials due to the high risk-to-benefit ratio. 
10 
 
Dexamethasone, a synthetic glucocorticoid, is the most commonly used anti-inflammatory 
agent to prevent FBR26, 27, 29, 31. Due to its potency, only small amounts of dexamethasone are 
required; this is essential for small implants where space is limited. Implant coatings designed to 
suppress the FBR for implantable glucose biosensors have been previously reported and their 
efficacy has been tested in several rat models (normal, diabetic, and obese) for one and three month 
implantation durations9, 11, 28, 42-46. Dexamethasone was delivered throughout the implantation 
period by incorporation in poly(lactic-co-glycolic acid) (PLGA) microspheres that were embedded 
in a polyvinyl alcohol (PVA) hydrogel coating. While studying the efficacy of these coatings in 
small animals is necessary as proof-of-concept, it is accepted that studies in larger animals are 
required in order to extrapolate the results to design the first-in-human clinical trials. The 
Goettingen minipig, a breed of miniature swine, is a common animal model for dermal studies due 
to the similarities between human and swine skin47-50. The objective of the present work was to 
study the FBR to miniaturized implantable biomaterials in the Goettingen minipig, identify key 
parameters that will determine anti-FBR dosing regimens of dexamethasone, and apply the 
findings for long-term prevention of the FBR. To achieve this, PLGA microsphere/PVA hydrogel 
composites that release dexamethasone in various amounts and rates (as determined in previously 
published work from our group51) were prepared. The composites were used to coat silicon chips, 
mimicking an implantable biosensor, and were implanted in the subcutaneous tissue of Goettingen 
minipigs. The local tissue reaction to the implants was determined histologically at multiple time 
points after implantation. 
2.2. Materials and Methods 
2.2.1. Materials 
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Dexamethasone was purchased from Cayman Chemical Company (Ann Arbor, MI). High-
molecular weight poly(vinyl alcohol) (HMW-PVA, MW 30–70 kDa), was purchased from 
Polysciences, Inc. (Warrington, PA) and low-molecular weight PVA (LMW-PVA, 99 % 
hydrolyzed, MW 133 kDa) was purchased from Sigma-Aldrich (St. Louis, MO). PLGA Resomer® 
RG503H (inherent viscosity 0.32–0.44 dl/g) was a gift from Boehringer-Ingelheim and PLGA 
DLG2A (inherent viscosity 0.15–0.25 dl/g), was a gift from SurModics Pharmaceuticals 
(Birmingham, AL). Methylene chloride and dimethyl sulfoxide (DMSO, ACS grade) were 
purchased from Fisher Scientific (Pittsburghm, PA).  
2.2.2. PLGA microsphere preparation. 
Dexamethasone-loaded PLGA microspheres were prepared as previously described9. Briefly, 
2 g of PLGA were dissolved in 8 ml methylene chloride (DCM). 200 mg of crystalline 
dexamethasone were added to the polymer solution and the mixture was homogenized at 10,000 
rpm for 2.5 min using a T 25 digital ULTRA-TURRAX® homogenizer (IKA® Works, Inc.) to 
obtain a homogenous suspension. The suspension was subsequently transferred to 40 ml of 1% 
w/v LMW-PVA aqueous solution and homogenized for 1 min at 10,000 rpm to obtain a solid-oil-
water emulsion. The emulsion was transferred to 500 ml of 0.1% w/v LMW-PVA aqueous solution 
and stirred at 600 rpm under vacuum for 3 hours to remove the DCM. The hardened microspheres 
were purified via three centrifugation cycles at 3,500 rpm for 2 min each, freeze dried and stored 
at 4 oC until further use. Blank microspheres were prepared in the same way without the addition 
of dexamethasone. PLGA polymers of two molecular weights were used in different preparations: 
25,000 g/mol (50:50 Resomer 503H) and 12,000 g/mol (50:50 DLG 2A). 
2.2.3. Preparation of implants 
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Implants were of cylindrical shape and consisted of a rectangular silicon chip core (5x0.5x0.5 
mm) coated with PVA hydrogel embedded with PLGA microspheres (7-11 mm length, 1.5 mm 
diameter when hydrated). To coat the silicon chips, 75 or 150 mg of microspheres were suspended 
in 1 ml of 5% w/v HMW-PVA aqueous solution. The mixture was vortexed and placed in a 
sonicated bath for 10 seconds to achieve good microsphere distribution and break any aggregates. 
The PVA hydrogel was formed after physical crosslinking of the HMW-PVA via three freeze thaw 
cycles. First, the suspension was subjected to one freeze-thaw cycle (2 h at -20 oC and 1 h at 
ambient temperature). After the first cycle, the partially thickened suspension was fed in a two-
piece grooved mold (grooves of 1.5 mm in diameter). The silicon chips were sandwiched between 
the two mold pieces that were then subjected to two more freeze-thaw cycles to complete the PVA 
crosslinking and form a self-supporting hydrogel around the chips. Each mold was used to coat 30 
silicon chips of approximately 2 mg weight. Please note that low-molecular weight PVA was used 
as a surfactant to improve emulsion stability during the microsphere preparation process, while 
high-molecular weight PVA was used to form a hydrogel. Hydrogel strips containing the silicon 
chips were air-dried and cut at 7, 9 or 11 mm length implants. The implants were placed in 16 
gauge needles and stored at 4 oC until further use. Different implant formulations were labeled as 
shown in Table 2.1. 
2.2.4. PLGA microsphere characterization 
Particle size: An Accusizer 780 (Particle Sizing Systems) was used to measure the particle size 
of the PLGA microspheres. 3-5 mg of dried microspheres were suspended in 1 ml of 0.1% w/v 
LMW-PVA solution, bath-sonicated for 10 s and analyzed for volume-based average size. 
Dexamethasone loading: 5 mg of dried microspheres or composites were dissolved in 1 ml 
DMSO and then diluted 10 times in phosphate buffered saline (PBS) pH 7.4. Dexamethasone 
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concentration was determined via RP-HPLC (PerkinElmer, Inc.). Mobile phase: 
acetonitrile/water/phosphoric acid (30/70/0.5%, v/v/v); column: Zorbax® C18 (4.6 mm×15 cm); 
detection wavelength: 240 nm; flow rate: 1 ml/min. 
2.2.5. In vivo pharmacodynamics study 
Seven young, female Goettingen minipigs were used as a large animal model to study the 
inhibition of the FBR to subcutaneous implants. Minipigs were studied in iterations of 2 or 3 
animals. The number of animals that were utilized for each formulation is indicated in the figure 
legends. Each study lasted for 30 days. The implants that were tested are shown in Table 2.1. They 
were implanted at the back of the animals on days 0, 9, 16, 23, 27, and 29. All implants were 
spaced at least 5 cm apart to ensure no interference. The area right above the spinal cord was not 
implanted. The animals were sacrificed on day 30 and the implants with surrounding subcutaneous 
tissue were harvested and stored in 10% buffered formalin solution (Sigma-Aldrich Co. LLC.). 
This resulted in implants being excised on days 1, 3, 7, 14, 21, and 30 post-implantation. All time 
points were ± 3 days to allow for unforeseeable delays. The extracted implants that prevented the 
FBR were analyzed for the remaining dexamethasone content. All animal studies were reviewed 
and approved by the University of Connecticut’s Institutional Animal Care and Use Committee 
(IACUC) prior to the beginning of the experiments. 
2.2.6. Histological evaluation 
Fixed tissues were processed, embedded in paraffin and sectioned in 20 μm films at the 
University of Connecticut’s Pathobiology Department. Tissue sections were stained with 
Hematoxylin & Eosin (H&E) and the presence and progress of the FBR was evaluated by 
observation under a light microscope. Normal connective tissue appears pink, adipose tissue white, 
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deposited collagen fibers light pink, and inflammatory cells purple. Digital images representative 
of the tissue reaction around the implants are presented here. 
2.3. Results 
2.3.1. Microsphere characterization 
Physical properties of the microspheres were measured to confirm that the formulations were 
consistent with the previous work51. The particle size and drug loading of the microspheres are 
shown in Table 2.2. Please note that due to the low solubility of dexamethasone in water and some 
polymer loss during microsphere preparation, the dexamethasone loading exceeded the theoretical 
(10% by weight). 
2.3.2. FBR to implants with no dexamethasone 
Implants coated with blank (no dexamethasone) microspheres embedded in PVA hydrogel 
were used to study the FBR in Goettingen minipigs. Tissue sections excised at 3, 7, 14, 21 and 30 
days after implantation give a representation of the progress of the FBR (Figure 2.1). 
The FBR consisted of the typical acute phase observed on day 3 (indicated by the presence of 
purple-stained inflammatory cells around the implant), and the chronic phase with fibrous 
encapsulation clearly visible from day 14 onwards (observed as a light pink band with collagen 
fibers oriented around the implant). Collagen deposition around the implant can be clearly seen on 
day 7 prior to fibrous encapsulation (Figure 2.2). 
2.3.3. Effect of total dexamethasone dose 
Implants coated with dexamethasone-loaded composites were used to determine whether the 
formulation that was effective in normal, diabetic and obese rats can be used in large animals. 
Implant R was the reference formulation which had the same composition as that which was 
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effective in all rat models9. Implants with higher dexamethasone doses were also tested in order 
to optimize the dexamethasone dosing. Two strategies to increase the total dexamethasone per 
implant were employed: a) doubling the microsphere density in the coating to 150 mg per 1 ml of 
PVA hydrogel (the maximum microsphere content that allows enough glucose permeability 
through the implant as determined in previous studies, unpublished data by Burgess et. al.); and 
b) increasing the implant length from 7 to 11 mm. All implant preparations are detailed in Table 
2.1.  
As shown in Figure 2.3, the implants with the higher dexamethasone doses (implants R150 and 
R11) completely suppressed the acute inflammation as no cell infiltration was observed on day 3 
post-implantation. Implants R and R9 with lower dexamethasone doses, including the reference 
implant, did not completely prevent the acute inflammatory phase but did reduce it significantly 
compared to the control. However, none of the implants prevented the chronic phase of the FBR, 
and collagen deposition is observed from day 7 in all cases, with the fibrous capsule being observed 
from day 14. The implants with the higher dexamethasone doses (implants R150 and R11) showed 
relatively less dense fibrous capsules compared to the control implants, however, this is not 
satisfactory for the purpose of long-term prevention of FBR to prolong the functionality of 
implantable biomaterials. 
2.3.4. Effect of PLGA molecular weight 
Implants made with PLGA microspheres of lower molecular weight were tested. These 
microspheres release dexamethasone continuously for two weeks, with no lag phase, as previously 
reported51. A formulation with lower molecular weight PLGA microspheres loaded in PVA 
hydrogels with the maximum amount (150 mg per 1 ml hydrogel) was tested (implant R2W). As 
shown in Figure 2.4 this formulation prevented acute inflammation (no inflammatory cell 
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accumulation, pane A in Figure 2.4) as well as chronic inflammation (no fibrous encapsulation, 
panel D in Figure 2.4) up to day 11. Minimal collagen deposition was observed on day 14 when 
dexamethasone was depleted. Implants extracted 1 and 14 days after implantation were analyzed 
for dexamethasone content. It was determined that after 24 hours, 61.56 ± 5.72 % of 
dexamethasone remained in the implant (i.e. 35.16 ± 5.72 % released during the burst phase) while 
7.77 ± 1.82 % remained in the implant at the end of 14 days (i.e. 92.81 ± 1.82 % released). 
Accordingly, the effective dexamethasone dose was calculated based on 40% of the total 
dexamethasone released during the first 24 hours and the rest continuously released throughout the 
implantation period (approximately 100 μg released the first day and 10 μg/day throughout the 
remainder of the implantation period). 
2.4. Discussion 
Local delivery of dexamethasone, an anti-inflammatory agent, has been successfully used to 
counter the FBR to subcutaneously-implanted biomaterials in normal, obese and diabetic rats. In 
order to translate this technology to the clinic, it was decided to bridge the gap between rats and 
humans by using a large animal model, Goettingen minipigs. The progress and prevention of the 
FBR was studied, with the intention to directly compare the finding with corresponding 
investigations in rats. Direct comparison was made possible by starting with implants with the 
same characteristics as the ones that were previously tested in rats (size, shape, mechanical 
properties, materials, anti-inflammatory drug)9. Our results reveal critical factors that need to be 
taken into consideration when extrapolating this type of data across different species. 
It was found that while the events leading to fibrotic encapsulation are similar between 
minipigs and rats, their timing differs significantly. In rats, fibroblast recruitment and activation 
starts 14 days after implantation42, while in minipigs active fibroblasts and collagen deposition can 
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be observed from day 7. This is shown in Figure 2.1 panel c and in Figure 2.2 where a dense 
collagen network surrounds the implant. This network will later on contract to form the fibrotic 
membrane isolating the implant. In the corresponding studies in rats, no dense collagen network 
was observed on day 7 after implantation. Instead, loose connective tissue similar to subcutaneous 
tissue under normal conditions was observed. The difference in the onset of fibrosis between rats 
and minipigs is of great importance as it indicates a difference in the severity of the chronic 
inflammation between the two species and consequently the amount of drug necessary to counter 
it.  
In transition from small to large animals during preclinical testing of drug-releasing 
formulations, dose is usually scaled up according to body weight with corrections based on 
empirical formulas. In the case of locally-acting implants, however, dose scale-up is not necessary 
as no systemic effect is desired. In order to prevent the FBR to devices implanted in the 
subcutaneous tissue, a minimum level of drug has to be maintained in the local environment 
throughout the implantation period. This level may vary from species to species due to differences 
in drug clearance from the subcutaneous tissue, drug diffusion rates through the tissue, drug 
metabolism and the presence of cells.  
Implants made of PLGA microspheres of the same molecular weight as the ones tested in rats 
and same total dexamethasone loading were used as reference formulations. These implants did 
not prevent the FBR and the tissue surrounding them was similar to that around the control 
implants. As evidenced by the absence of inflammatory cell accumulation in Figure 2.3, higher 
dexamethasone doses prevented the acute phase of the FBR. The higher dexamethasone doses 
were achieved by either increasing the microsphere density in the biocompatible coating or 
increasing the total length of the implants. However, increasing the dexamethasone dose was 
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limited due to the small size of the implants. The maximum amount of dexamethasone per implant 
that was achieved was 0.22 mg. This amount was not enough to prevent fibrous encapsulation of 
the implants.  
Based on the in vitro dissolution testing of these implants51, 40% of the drug is released within 
the first 24 hours and the remaining amount is released continuously starting from about day 10 
post-implantation. This leaves a nine-day period with little-to-no dexamethasone release in the 
tissue (lag phase). The lag phase did not interfere with the anti-FBR effect of the implants in rats. 
Based on the observations on the earlier timing of fibrosis onset in minipigs compared to rats, it 
was hypothesized that eliminating this lag phase might prevent FBR. This hypothesis was tested 
and confirmed using PLGA microspheres of a lower molecular weight. Implants made with these 
microspheres release dexamethasone continuously for about 14 days with no lag phase51. Once 
implanted in the minipigs, the implants prevented the FBR until day 11 and early collagen 
deposition is observed on day 14. This is likely due to the dexamethasone depletion that occurs 
around that time. 
Based on the results discussed above, the dexamethasone dose that is effective to counter the 
FBR in Goettingen minipigs is ~100 μg released during the first day (to counter the acute 
inflammation cause by tissue trauma) and about 10 μg/day released continuously throughout the 
implantation period (to prevent fibroblast activation and collagen deposition). This was confirmed 
following analysis of the amount of dexamethasone remaining in exctracted implants at 24 hours 
and 14 days. This dosing regimen applies to subcutaneously-implanted materials of small size 
(around 7x1.5 mm when hydrated). It has been previously shown that the size of the implant affects 
the severity of the FBR in rats, so dose adjustment will likely be necessary for implants of different 
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sizes. The release kinetics of dexamethasone, however, will have to remain the same, i.e. a burst 
release followed by a continuous, zero-order release throughout the implantation period.  
The size of our implants was chosen to reflect the trend of miniaturization of implantable 
medical devices. The extent of the anti-inflammatory drug dose limitation varies from implant to 
implant and it depends on implant size, desired coating thickness, desired coating permeability to 
various tissue molecules, and the type of controlled release vesicle used to deliver the drug. In 
order to extend the anti-FBR effect of the biomaterials beyond the two-week period achieved here, 
the drug-carrier technology (in this case the PLGA microspheres) has to be optimized or replaced 
in order to maximize the drug loading efficiency and accommodate high dexamethasone doses in 
such small samples.  
2.5. Conclusions 
In the present work, the FBR to subcutaneous implants was compared between a small and 
large animal model for the first time. The onset and severity of fibrosis was identified as a key 
difference with minipigs, demonstrating earlier onset and more severe chronic inflammation 
compared to rats. It was determined that the dexamethasone release from the implant coatings must 
be tailored to the species-specific stages of the FBR. In order to counter the more severe chronic 
inflammation observed in minipigs compared to rats, dexamethasone release must be continuous, 
with no lag phase. The effective dexamethasone dosing regime was 100 μg during the first day 
and 10 μg/day thereafter; this regime is applicable to implants of similar size (7 x 0.15 mm) and 
can be extrapolated to longer implantation periods in minipigs. Lastly, these findings can facilitate 
the dose calculations in the first-in-human studies as porcine skin is the optimal model for dermal 
formulations.  
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Chapter 3 
Development of Dexamethasone-Loaded PLGA Microspheres for Long-Term 
Prevention of the Foreign Body Reaction in Gottingen Minipigs 
Abstract 
An important strategy currently used to prevent the foreign body reaction (FBR) to subcutaneous 
implants in animal models is the constant release of dexamethasone in the tissue surrounding the 
implant. There have been few studies in large animal models including: 1) a bulky osmotic pump 
system that delivers dexamethasone over a one-month period; and 2) a poly(lactic-co-glycolic 
acid) (PLGA) microsphere/polyvinyl alcohol (PVA) hydrogel composite coating for miniaturized 
implants that locally delivers dexamethasone for a two-week period in minipigs. A long-term 
strategy to prevent FBR to subcutaneous implants in a large animal model is necessary. In this 
work, a PLGA microsphere/PVA hydrogel composite coating for the one-month prevention of the 
FBR in Gottingen minipigs was developed. This coating is suitable for miniaturized implantable 
devices (of a few mm length), such as biosensors, that require constant communication with the 
local microenvironment to function. The microspheres were prepared via dexamethasone/polymer 
co-precipitation which resulted homogeneous distribution of dexamethasone in the microsphere 
matrix which in turn gave rise to increased drug loading, low burst release, and minimal lag phase. 
The in vivo functionality of the composite coatings was evaluated via histological examination of 
explanted tissue samples from the area surrounding the implants. 
Keywords: PLGA microspheres; dexamethasone; foreign body reaction; swine; co-precipitation. 
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3.1. Introduction 
Once implanted, biomaterials face the host tissue’s response (foreign body reaction, FBR) 
which often interferes with their intended action1-8. The final result of the FBR is isolation of the 
implant from the surrounding tissue via fibrous encapsulation9-11. This can inhibit drug transport 
in the case of drug-delivering biomaterials, prevents healing in the case of tissue engineering 
scaffolds, and stops analyte diffusion in the case of implantable biosensors. The effect of, as well 
as the prevention of FBR for various types of biomaterials has been studied using different animal 
models11-14.  
The FBR consists of a cascade of events that includes, among others, inflammatory cell 
recruitment, collagen deposition, and formation of an avascular fibrotic capsule around the foreign 
body. Most of these steps are preserved across different species, however, some differences exist. 
It has been reported that diabetic rats lack the high levels of mast cells that are observed in normal 
rat subcutaneous tissue during the FBR15. The function of mast cells is to exacerbate acute 
inflammation and as a result diabetic rats show a less severe response in the days immediately 
following implantation. Other parts of the FBR have been compared between different species, 
such as nitric oxide production from human, mouse and rat macrophages16 and the presence of 
basophilic granules in humans and pigs17, 18.  
Our group has previously developed poly(lactic-co-glycolic acid) (PLGA) 
microsphere/polyvinyl alcohol (PVA) hydrogel-based composites capable of preventing the FBR 
to subcutaneously-implanted materials15, 19-24. This is achieved via delivery of dexamethasone, a 
synthetic corticosteroid with potent anti-inflammatory properties. The dexamethasone dose and 
release kinetics have been optimized for up to a three-month implantation period19 in rat models 
(normal, type 1 diabetic, obese15) as well as in a large animal model (Gottingen minipigs) for a 
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two-week implantation period. Ward et al. have studied the anti-inflammatory effect of 
subcutaneously delivered dexamethasone for one month in minipigs. However, they delivered 
large amounts of dexamethasone (ranging from 3 to 42 mg/implant or 0.05 to 0.7 mg/Kg body 
weight). Such large amounts of dexamethasone are not necessary for local prevention of FBR, can 
cause systemic effects, and cannot be incorporated around miniaturized implants (for example 
biosensors of a few millimeters in length). Accordingly, a method to deliver small amounts (less 
than one mg) of dexamethasone effectively to prevent FBR in a large animal model is necessary.  
It was previously determined that: a) high dexamethasone loading in PLGA microspheres is 
necessary to provide sufficient drug to last for a one-month implantation period in minipigs; and 
b) a lag phase in the dexamethasone release profile is detrimental in preventing FBR in minipigs. 
Accordingly, in the present work a new PLGA microsphere formulation with high drug loading 
efficiency and no lag phase was developed. The new PLGA formulation was prepared via 
dexamethasone-PLGA co-precipitation rather than dexamethasone crystal dispersion in the PLGA 
matrix and its anti-FBR efficacy was tested in Gottingen minipigs for a one-month implantation 
period. 
3.2. Materials and Methods 
3.2.1. Materials 
Dexamethasone was purchased from Cayman Chemical Company (Ann Arbor, MI). High-
molecular weight poly(vinyl alcohol) (HMW-PVA, MW 30–70 kDa), was purchased from 
Polysciences, Inc. (Warrington, PA) and low-molecular weight PVA (LMW-PVA, 99 % 
hydrolyzed, MW 133 kDa) was purchased from Sigma-Aldrich (St. Louis, MO). PLGA Resomer® 
RG503H (inherent viscosity 0.32–0.44 dl/g) was a gift from Boehringer-Ingelheim and PLGA 
DLG2A (inherent viscosity 0.15–0.25 dl/g), was a gift from SurModics Pharmaceuticals 
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(Birmingham, AL). Methylene chloride and dimethyl sulfoxide (DMSO, ACS grade) were 
purchased from Fisher Scientific (Pittsburghm, PA). 
3.2.2. Microsphere preparation 
50 mg of dexamethasone were dissolved in a small amount of DMSO (0-200 μl). 200 mg 
PLGA were dissolved in 0.4 ml of DCM in a 50-ml Teflon vial. The dexamethasone solution was 
transferred into the polymer solution and vortexed at 3,000 rpm for 10 s to achieve a homogenous 
mixture. 10 or 20 ml of aqueous phase consisting of 1% w/v PVA in water and 0-30% v/v DMSO 
were added in the Teflon vial while vortexing at 3,000 rpm. The resulting emulsion was diluted in 
380 ml Milli-Q water and was held at ambient temperature and pressure for 3 hours under stirring 
at 600 rpm. After 3 hours, stirring continued under vacuum for 30 min to remove any residual 
DMSO. The hardened microspheres were collected and any free PVA, DMSO and dexamethasone 
was removed via three centrifugation and washing (Milli-Q water) cycles at 3,500 rpm for 2 min 
each. The microspheres were subsequently freeze-dried and stored at 4 °C until further use. 
3.2.3. Optimization of microsphere preparation method 
The above method was optimized for dexamethasone solution volume, DMSO concentration 
in the aqueous phase, total volume of aqueous phase and dilution in Milli-Q water. The emulsions 
were monitored under a polarized light microscope (PLM) in order to pinpoint the position and 
timing of dexamethasone precipitation (inside vs. outside the emulsion droplets). The optimized 
formulation (slow homogeneous precipitation of dexamethasone within the emulsion droplets) was 
tested for burst release (dexamethasone released after 24 hours incubation at 37 °C, in 10 mM 
PBS) and was chosen for the remaining studies. A formulation where dexamethasone was not 
dissolved in DMSO but was suspended in the polymer solution was used as a negative control. 
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3.2.4.  Characterization of PLGA microspheres 
Particle size: An Accusizer 780 (Particle Sizing Systems) was used to measure the particle size of 
the PLGA microspheres. 3-5 mg of dried microspheres were suspended in 1 ml of 0.1% w/v PVA 
solution, bath-sonicated for 10 seconds (to break up any aggregates) and analyzed for volume-
based average size. 
Dexamethasone loading: 5 mg of dried microspheres or composites were dissolved in 1 ml DMSO 
and then diluted 10 times in phosphate buffered saline (PBS) pH 7.4. Dexamethasone 
concentration was determined via RP-HPLC (PerkinElmer, Inc.). Mobile phase: 
acetonitrile/water/phosphoric acid (30/70/0.5%, v/v/v); column: Zorbax® C18 (4.6 mm×15 cm); 
detection wavelength: 240 nm; flow rate: 1 ml/min. 
3.2.5.  Preparation of composite coatings 
150 mg PLGA microspheres and 9 mg crystalline dexamethasone were added to 1 ml of PVA 
solution in water (5% w/v) and the mixture was bath-sonicated for 10 seconds to achieve a 
homogenous suspension. Please note that the coatings were spiked with crystalline dexamethasone 
to achieve approximately 100 μg dexamethasone release from each implant within the first 24 
hours (due to the low burst release of the microspheres). This amount of burst release is necessary 
to prevent the first part of the FBR (acute inflammation) based on our previous studies. Small 
silicon chips (5x0.5x0.5 mm, used to mimic small implantable devices) were sandwiched between 
a two-piece grooved mold containing the microsphere/PVA suspension. The mold was subjected 
to three freeze-thaw cycles (2 h at -20 °C, 1 h at ambient temperature) to physically cross-link the 
PVA solution into a hydrogel that encloses the silicon chips. The coated chips were removed from 
the mold and cut into 7 mm length pieces, air-dried for 3 hours and stored at 4 °C until further use.  
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3.2.6.  In vitro release testing of the composite coatings 
Composites were placed in 10 ml of 10 mM PBS with 0.1% w/v sodium azide in amber vials. 
The vials were placed in a water-bath at 37 °C with stirring (100 rpm). The entire media volume 
was replaced periodically to ensure maintenance of sink conditions (total dexamethasone 
concentration in the media never exceeded 10% of the equilibrium solubility) and avoid the 
complication of dexamethasone degradation. The concentration of dexamethasone in the media 
was measured via HPLC as described above. 
3.2.7.  In vivo study 
Six female Gottingen minipigs (4 months old) were used in this study. Three types of 
composites were studied: (A) coated chips with no dexamethasone, using blank PLGA 
microspheres as a negative control; (B) coated chips with optimized dexamethasone-loaded PLGA 
microspheres and crystalline dexamethasone; and (C) composites without silicon chips at the core 
with dexamethasone-loaded microspheres and crystalline dexamethasone. Group C was 
investigated in case the dexamethasone loaded in group B was insufficient to prevent FBR. Each 
minipig received three implants (subcutaneously injected at the back of the animals through a 16 
G needle) on days 0, 9, 16, 23 and 27 and the animals were sacrificed on day 30. This resulted in 
samples being excised 3, 7, 14, 21 and 30 days after implantation. Excised composites with the 
surrounding tissue were fixed in 10% buffered formalin, and thin sections (20 μm) were stained 
using Hematoxylin & Eosin staining (H&E). H&E staining was chosen instead of Masson’s 
trichrome (which stains collagen fibers blue). Due to the highly collagenous nature of swine 
subcutaneous tissue, slides that were stained with Masson’s trichrome did not differentiate 
cytoplasm, interstitial fluid, and collagen deposition, since everything was stained blue. All animal 
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studies were reviewed and approved by the University of Connecticut’s Institutional Animal Care 
and Use Committee. 
3.2.8.  Statistical analysis 
All reported values are average values ± standard deviation based on three repetitions. The 
histological data were of a qualitative nature (presence or absence of inflammation) and 
representative images are shown.  
3.3. Results 
3.3.1. Optimization of microsphere preparation method 
Rather than the typical method of suspending dexamethasone crystals in a PLGA solution, in 
this work the encapsulation of dexamethasone in PLGA microspheres was achieved by co-
precipitation of dexamethasone and PLGA. The process was optimized in a pilot study where the 
precipitation of dexamethasone was visualized via PLM. Figure 3.1 shows two characteristic 
images: a) non-optimized process (no added DMSO in the external water phase which would have 
slowed down dexamethasone precipitation) where the dexamethasone crystals are observed 
outside the polymer phase (emulsion droplets); and b) optimized process where the dexamethasone 
crystals are located inside the polymer phase (emulsion droplets). 
The optimized process is as mentioned in the Methods section 2.2, with the following 
specifications: 100 μl DMSO used to dissolve 50 mg of dexamethasone; 20 ml total volume of 
external aqueous phase; 30% v/v DMSO in the external aqueous phase; and primary emulsion 
dilution in 380 ml Milli-Q water. The optimized formulation was compared with the negative 
control formulation and representative images are shown in Figure 3.2. 
3.3.2. Microsphere characterization 
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The optimized PLGA microspheres had a dexamethasone loading of 9 ± 0.13 % w/w, burst 
release (within 24 hours at 37 °C in 10 mM PBS pH 7.4) of 1.22 ± 0.17 %, and average size (based 
on volume distribution) of 36.36 ± 7.79 μm. 
3.3.3.  In vitro release 
The release profile of dexamethasone from the composite coatings with the optimized PLGA 
microsphere formulation is shown in Figure 3.3. During the first 24 hours approximately 40 % of 
dexamethasone was released, which is as expected since the crystalline dexamethasone added to 
the composites accounted for 40 % of the total dexamethasone. A further 15 % was released during 
days 2 and 3. From day 4 onwards, sustained release of dexamethasone was observed, which 
exceeded 90 % of the total amount of drug in the composites by day 45. This portion of the release 
profile was approximately zero order with R2 = 0.9931. 
3.3.4. In vivo evaluation of the anti-FBR properties of the composite coatings 
Figure 3.4 shows the progress of the FBR from day 3 to day 30 post-implantation for control 
implants (coated with blank composite coating, no dexamethasone). The results are consistent with 
what has been reported previously, i.e. inflammatory cell accumulation observed on day 3 and 
collagen deposition from day 7. A fibrous capsule can be seen from day 14 onwards. 
As shown in Figure 3.5, silicon chips coated with dexamethasone-releasing composites 
negated the FBR for the 30-day implantation period. No accumulation of inflammatory cells or 
fibrous encapsulation was visible in any of the tissue samples. 
The same observation has been made when the composites without silicon chips in their inner 
core were tested, as shown in Figure 3.6. 
32 
 
3.4. Discussion 
Similarities between human and swine skin make the Gottingen minipig a good large animal 
model to investigate the prevention of FBR to subcutaneous implants26. In the previous chapter, it 
has been determined that minipigs require higher levels of dexamethasone released in the local 
microenvironment to prevent FBR compared to rats. In addition, the existence of a release lag 
phase between days 1 and 10 was detrimental to the anti-FBR effect of the composites in the 
minipig model but not in the rat models. In this work, we utilized the knowledge gained from our 
previous studies to develop a one-month dexamethasone-releasing composite coating that was 
capable of preventing FBR in minipigs. 
Previously, dexamethasone has been encapsulated in PLGA microspheres by suspending 
micronized dexamethasone crystals in a PLGA solution and further emulsifying the suspension in 
an aqueous phase followed by organic solvent extraction and microsphere formation23, 27, 28. This 
formulation showed a lag phase in the one-month release profile21, 29, 30. It was hypothesized that 
the lag phase was due to poor drug distribution in the microsphere matrix and that improving the 
drug distribution would minimize the lag phase. 
Instead of suspending dexamethasone crystals in the PLGA solution, a co-solvent system 
(DCM/DMSO) to dissolve both dexamethasone and PLGA in the oil phase was used. Further, the 
process parameters were adjusted to ensure that dexamethasone precipitates immediately before 
PLGA. This facilitated the encapsulation of dexamethasone as small crystals throughout the 
polymer matrix. The inclusion of DMSO in the outer water phase (30% v/v) was crucial in 
achieving this, as it slowed down the diffusion of DMSO from the oil to the water phase and thus 
the precipitation of dexamethasone. Moreover, the ratio of the co-solvents in the inner oil phase 
was crucial to achieving timely dexamethasone precipitation and was optimized at 4:1 
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DCM:DMSO by volume. Lastly, dilution of the emulsion in a large volume of water ensured that 
PLGA precipitated immediately after dexamethasone precipitation. These parameters were 
optimized by utilizing PLM to monitor drug precipitation during processing, as shown in Figure 
3.1 and Figure 3.2.  
The optimized microsphere formulation was incorporated into the PVA hydrogel and was 
tested for in vitro release. The composites were spiked with crystalline dexamethasone to 
accommodate the lack of dexamethasone release during the first 24 hours. This additional 
dexamethasone accounted for 40% of the total drug content of the composites. As expected, the 
free dexamethasone was released rapidly from the composites, with 40% release during the first 
24 hours. This release is crucial to negating the acute inflammatory phase. A further 15% of 
dexamethasone was released during days 2 and 3, which is likely due to release of dexamethasone 
encapsulated near the surface of the microspheres or inside smaller microspheres. From day 4 until 
day 45, dexamethasone was constantly released at an approximately zero order rate (more than 
90% cumulative drug release). The slight deviation from linearity (R2 = 0.9931) during this release 
period may be due to the wide size distribution of the microspheres, with the smaller microspheres 
contributing more near the beginning of the release and the larger microspheres contributing more 
towards the end of the release profile. Another possible reason for this deviation from linearity is 
the degradation pattern of PLGA, which undergoes auto-catalyzed degradation through the 
generation of hydrogen ions that facilitate hydrolysis.  
Composites made with the optimized PLGA formulation were tested in Goettingen minipigs 
for their efficacy in preventing the FBR for one month. It was determined that the FBR can be 
completely negated by the constant release of dexamethasone throughout the implantation period. 
In addition, implants made of composites with no silicon chips in their core (to allow for higher 
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dexamethasone loading) were investigated and it was shown that these also prevented FBR. The 
need for higher dexamethasone doses in minipigs compared to rats (which were the focus of 
previous research) is likely due to the highly collagenous nature of the swine subcutaneous tissue. 
This results in more severe and earlier appearance of fibrosis. While the in vivo studies were 
conducted for a period of 30 days, the in vitro release studies revealed dexamethasone release for 
45 days. Accordingly, these composites may be useful to prevent FBR for more than 30 days, 
however, this has not yet been tested in vivo and will be part of future investigations.  
3.5. Conclusions 
A novel method for the preparation of microspheres containing insoluble drugs was developed 
to achieve homogeneous drug distribution, high loading and low burst release. Dexamethasone 
microspheres prepared by this method, together with crystalline dexamethasone, were utilized in 
microsphere/hydrogel composite coatings to achieve an approximately 40% burst release followed 
by a constant drug release pattern with no lag phase. This microsphere/hydrogel composite coating 
formulation successfully prevented FBR in a large animal model for a period of one month via 
localized release of low doses of dexamethasone (approximately 10 μg per day, which is close to 
1000 times below the level that which would result in any systemic effects (0.75 to 9 mg per day). 
To the best of the authors’ knowledge, this is the first time that such low doses of dexamethasone, 
suitable for miniaturized medical devices such as biosensors, have been used to prevent FBR in a 
large animal model. 
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Chapter 4 
Prevention of the Foreign Body Reaction and Promotion of Angiogenesis around 
Subcutaneous Implants 
Abstract 
Dexamethasone-releasing PLGA poly(lactic-co-glycolic acid) microsphere/PVA (polyvinyl 
alcohol)  hydrogel composite coatings have been shown to prevent the foreign body reaction (FBR) 
to subcutaneous implants in small and large animal models. Such coatings were developed to 
extend the lifetime of implantable biosensors. However, long-term exposure of tissue to low levels 
of dexamethasone results in a reduction in blood vessel density due to the anti-angiogenic effect 
of dexamethasone. This mild effect, while not threatening to the subject’s health, may interfere 
with analyte detection and sensor response time over the long-term. VEGF has been previously 
incorporated into these coatings and the anti-angiogenic effect of dexamethasone was reduced. 
The present work focused on administration of combinations of three tissue response modifiers 
(TRMs), dexamethasone, VEGF and PDGF (platelet derived growth factor) which prevent the 
FBR, increase angiogenesis and promote blood vessel maturation (which increases blood flow), 
respectively. To minimize any potential interference among the three TRMs (for example, PDGF 
increases fibrosis), the relative doses of dexamethasone, VEGF and PDGF were adjusted. It was 
determined that: a) all three TRMs are required for maximum promotion of angiogenesis, blood 
vessel maturation and prevention of the FBR; b) VEGF has to be administered at higher doses than 
PDGF; c) an increase in dexamethasone dosing must be accompanied by a proportional increase 
in growth factor dosing; and d) modification of the TRM ratio can achieve a constant capillary 
density throughout the implantation period which is important for applications such as biosensors 
to maintain sensitivity and a stable sensor baseline.  
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4.1. Introduction 
Biosensors, defined as analytical devices that detect biological analytes, have progressed in 
their development and miniaturization such that fully-implantable sensors (usually in the 
subcutaneous tissue) will become a reality in the near future1-12. These sensors will provide real-
time, continuous monitoring of analytes, such as glucose, which are currently being monitored 
intermittently. Diabetic patients are a major group that will benefit from the realization of 
implantable biosensors, since tight blood glucose control is paramount to diabetic health. 
Once implanted, biosensors are attacked by the body’s defense mechanism, a cascade of events 
collectively known as the foreign body reaction (FBR) which results in the encapsulation of 
biosensors in a fibrous membrane that isolates them from the surrounding tissue and thus renders 
them ineffective13, 14. The FBR and its prevention have been a research focus during the past 
decades; the most common method to prevent the FBR is by the continuous administration of an 
anti-inflammatory agent, most commonly dexamethasone6, 13-16. Dexamethasone is popular due to 
its high efficacy and potency which result in only small amounts of the drug being required for 
long-term action. However, long-term exposure of a tissue to low levels of dexamethasone results 
in reduction in blood vessel density in the local area due to dexamethasone’s anti-angiogenic 
effect17-19. This mild effect, while not detrimental to the subject’s health, may interfere with analyte 
detection and sensor the response time. 
Glucose diffuses passively from the blood to the subcutaneous tissue where it can be detected 
by an implanted biosensor. The time it takes for glucose to travel from the capillary wall to the 
sensor surface is dependent on the distance it has to cover, and typically ranges from 6 to 15 
minutes20. Long-term exposure of dexamethasone decreases the number of capillaries available 
for glucose diffusion to the sensor, as well as increases the average distance between the capillaries 
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and the sensor surface. Both effects may significantly increase sensor response lag time as well as 
sensitivity. Accordingly, growth factors that promote angiogenesis can be administered alongside 
dexamethasone in order to prevent dexamethasone-induced ischemia and reduce glucose sensor 
lag times. VEGF (vascular endothelial growth factor) has successfully been administered with 
dexamethasone through poly(lactic-co-glycolic acid) (PLGA) microspheres embedded in a 
polyvinyl alcohol (PVA) hydrogel over a one-month period and an increase in capillary density 
was observed21. To further increase the capillary density around the implants, the current work 
focuses on administration of dexamethasone, VEGF and PDGF (platelet derived growth factor). 
VEGF promotes the migration of endothelial cells to the site, which form new branches on existing 
blood vessels22-25. PDGF promotes the maturation of the new branches by attracting pericytes that 
form an outer cellular layer on the new branches and connect venous and arterial blood flow26-29.  
It is known that angiogenesis and the FBR have some mechanistic overlap; cytokines that 
promote branching of existing blood vessels and recruitment of endothelial cells (primarily VEGF) 
exacerbate acute inflammation and inhibit chronic inflammation (which starts with the activation 
of fibroblasts)30-32. On the other hand, cytokines that promote the maturation of new blood vessel 
branches (primarily PDGF), via the recruitment of pericytes, promote chronic inflammation33-36. 
In addition, dexamethasone is well known to inhibit angiogenesis. It is therefore evident that the 
simultaneous release of these three molecules in a tissue will result in significant interference in 
their respective roles. In the current work, composite implants containing combinations of 
dexamethasone, VEGF and PDGF were investigated in the subcutaneous tissue using a rat model. 
The tissue surrounding the implants was examined via histological evaluation for prevention of 
the FBR and concurrent promotion of angiogenesis. Adjustment of the relative ratios of the three 
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TRMs eliminated interference among the TRMs that was observed for some of the composite 
combinations. 
4.2. Materials and Methods 
4.2.1. Materials 
Dexamethasone was purchased from Cayman Chemical Company (Ann Arbor, MI). VEGF, 
PDGF and their respective ELISA quantification kits were purchased from Peprotech (Rocky Hill, 
NJ). High-molecular weight polyvinyl alcohol (HMW-PVA, MW 133 kDa), was purchased from 
Polysciences, Inc. (Warrington, PA). Low-molecular weight PVA (LMW-PVA, 99% hydrolyzed, 
MW 30-700 kDa), bovine serum albumin (BSA), and BSA-FITC were purchased from Sigma-
Aldrich (St. Louis, MO). PLGA Resomer® RG503H (inherent viscosity 0.32–0.44 dl/g) was a gift 
from Boehringer-Ingelheim. Methylene chloride was purchased from Fisher Scientific 
(Pittsburghm, PA). Sprague Dawley rats were purchased from Charles River Laboratories 
(Willimantic, CT). 
4.2.2. Formulation of protein microspheres 
In a 50-ml Teflon vial, 500 mg of PLGA were added with 2 ml methylene chloride (DCM). 
After the polymer was dissolved, 200 μl of the protein phase (100 mg/ml BSA with either 5 μg 
VEGF (V_MS), 5 μg PDGF (P_MS) or 5 μg VEGF and 2.5 μg PDGF (VP_MS)) were added to 
the polymer solution. The vial was vortexed at 3,000 rpm for 10 seconds and homogenized at 
10,000 rpm for 30 seconds to achieve a water-in-oil primary emulsion. A secondary water-in-oil-
in-water emulsion was made by adding 10 ml water phase (1% w/v of LMW-PVA, with or without 
2% w/v NaCl) and vortexing at 3,000 rpm for 10 seconds. The secondary emulsion was diluted 
with 10 ml of Milli-Q water to speed up polymer precipitation and microsphere formation. The 
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diluted emulsion was kept under vacuum on a horizontal shaker at 300 rpm for 3 hours. The 
hardened microspheres were purified to remove LMW-PVA and non-encapsulated drug via three 
centrifugation cycles (2 min, 3,500 rpm), freeze dried overnight and stored at -20°C until further 
use. Formulations containing 2% w/w FITC-BSA (of the total BSA amount) were prepared to 
visualize the protein distribution inside the microspheres. All microsphere preparation steps took 
place in a single vial (from polymer dissolution in the organic solvent to microsphere storage), as 
demonstrated in Figure 4.1.  
4.2.3. Formulation of dexamethasone microspheres 
Dexamethasone-containing microspheres were prepared as above with the 200 μl protein 
solution replaced by 100 mg of crystalline dexamethasone. A homogenous drug suspension in the 
polymer solution was achieved following 2.5 min of homogenization at 10,000 rpm. 
4.2.4. Microsphere characterization 
Drug loading (dexamethasone): 5 mg of dried microspheres were dissolved in 1 ml DMSO 
and then diluted 10 times in phosphate buffered saline (PBS) pH 7.4. Dexamethasone 
concentration was determined via RP-HPLC (PerkinElmer, Inc.). Mobile phase 35% acetonitrile 
in water, 0.1% phosphoric acid; column C18 500x03 mm; and detection wavelength 240 nm. 
Drug loading (growth factors): 2 mg of dried microspheres were dissolved in 1 ml acetone, 
and the undissolved pellets were washed and collected via three centrifugation cycles (12,000 rpm, 
5 min) and dried under vacuum for 30 min to remove acetone. The pellets, which contained the 
proteins, were reconstituted in 1 ml of PBS containing 0.1% Tween 20. VEGF and PDGF ELISA 
kits were used to quantify the growth factor concentration in the reconstituted solutions, as per the 
manufacturer’s instructions. 
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Particle size: An Accusizer 780 (Particle Sizing Systems) was used to measure the particle 
size of the PLGA microspheres. 3-5 mg of dried microspheres were suspended in 1 ml of 0.1% 
w/v LMW PVA solution, bath-sonicated for 10 seconds to break any aggregates and analyzed for 
volume-based average size. 
Confocal microscopy: A Nikon A1R Spectral confocal microscope was used to visualize 
protein distribution inside the microspheres. Microspheres were suspended in distilled water prior 
to imaging, and FITC-BSA was detected at excitation and emission wavelengths of 494 and 518 
nm, respectively. 
4.2.5. Fabrication of composites 
A predetermined amount of PLGA microspheres were added to 1 ml of HMW-PVA solution 
in water (5% w/v) and the mixture was bath-sonicated for 10 seconds to achieve a homogenous 
suspension. The suspension was fed into stainless steel tubes with inner diameter 1.5 mm and 
subjected to three freeze-thaw cycles (2 h at -20°C, 1 h at ambient temperature) to physically cross-
link the HMW-PVA solution to form a hydrogel. The gels were removed from the tubes and cut 
at 5 mm length pieces, air-dried for 3 hours and stored at -20°C until further use. The different 
groups of composites prepared and their compositions are shown in Table 4.1.  
4.2.6. Investigation of VEGF-to-PDGF ratio 
Spraque Dawley rats (male, 150-200 g) were used as a small animal model (6 per group). Each 
rat was implanted with composites C, D, DV, DVP, and D2VPa (as defined in Table 4.1 above) 
on the dorsal area. Each member of a group of rats was implanted with four composites of the 
same type. Implants were spaced at least 2 cm apart to ensure no interference. Rats were euthanized 
30 days after implantation. After euthanasia, the composites with surrounding subcutaneous tissue 
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and skin were removed and fixed in 10% buffered formalin solution for 24 hours. They were then 
processed at UConn’s pathobiology services, embedded in paraffin blocks and cut into 20 μm-
thick sections. The samples were immune-stained against smooth muscle actin (sma), which stains 
mature blood vessels. 
4.2.7. Investigation of dexamethasone-to-growth factor ratio 
Based on the outcome of the growth factor ratio study, this investigation included composites 
D, DV, D2VPb as well as one with a higher dexamethasone dose (2D2VP). The study design was 
as described above with the following differences: Rats were euthanized on different days in 
groups of 6 (day 3, 7, 14, 21, and 30 following implantation). In addition to immune-staining 
against sma, the samples from the final study were also stained using a standard H&E protocol to 
monitor the anti-FBR effect of the composites. Anti-sma-stained tissue slides were examined via 
light microscopy, and the total number of capillaries within a distance of 200 μm around the 
implants were blind-counted, and the average values and standard deviations were calculated from 
three samples. 
All animal studies were reviewed and approved by the University of Connecticut’s Institutional 
Animal Care and Use Committee. 
4.3. Results 
4.3.1. Microsphere preparation and characterization 
Protein distribution inside the PLGA microspheres was optimized in a pilot study (using only 
BSA as model protein). 2% w/v of NaCl was added to the outer water phase to induce removal of 
the inner water phase through osmosis while leaving the protein molecules inside the polymer 
matrix. The microspheres were characterized for protein distribution, drug loading and burst 
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release. It was determined that by incorporation of NaCl in the outer water phase, protein 
distribution in the microsphere matrix improved significantly and the burst release was reduced, 
as shown in Figure 4.2. 
Dexamethasone- and growth factor-loaded PLGA microspheres were prepared with the 
optimized method described above, and were characterized for drug loading and particle size as 
shown in Table 4.2. 
4.3.2. VEGF-to-PDGF ratio 
The relative amounts of VEGF and PDGF were changed while dexamethasone dosing was 
kept constant. Figure 4.3 shows tissue samples around composites C, D, DV, DVP, D2VPa, as 
well as normal tissue (N) away from implantation sites at 30 days following implantation. Mature 
blood vessel walls stained red. As expected, control implants (C) with no dexamethasone, VEGF 
or PDGF, showed fibrosis (blue band around the implant). Implants D, which were loaded with 
dexamethasone but no growth factors, showed no fibrosis, and the blood vessel density around 
these implants was significantly lower than that of normal tissue. Implants DVP, which were 
loaded with equal amounts of VEGF and PDGF showed fibrosis and low blood vessel density near 
the surface of the implants. Implants D2VPa with a VEGF and PDGF ratio of 2:1 showed 
angiogenesis, with capillaries oriented around the implant.  
4.3.3. Adjustment of dexamethasone dose 
Based on the results of the previous study, implants D, DV, D2VPb and 2D2VP were used to 
investigate their anti-FBR effect throughout a one-month period. Figure 4.4 shows representative 
tissue sections from day 3 to day 30 following implantation for the different composites. No 
inflammation (infiltration of inflammatory cells present on day 3 and fibrotic band present from 
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day 14 onwards) was observed in any of the composites. This was expected for composites D 
which have previously been studied for their anti-FBR effect and were used as a control here. 
Composites that contained VEGF or combinations of VEGF and PDGF in addition to 
dexamethasone also showed no inflammation. In the combination composites (D2VPb and 
2D2VP), dexamethasone was loaded at two doses to confirm that the minimum effective dose 
previously determined for composites with only dexamethasone and VEGF is effective in the 
combination coatings. 
Figure 4.5 shows the angiogenic effect of the composites 7, 14, 21 and 30 days following 
implantation at a low magnification (10x). Higher-magnification (40x) images are shown in Figure 
4.6 and the capillary density around the implants was quantified as reported in Figure 4.7. The 
highest angiogenesis throughout the implantation period was achieved with composites D2VPb 
(P<0.001 compared to the control group), and the capillaries were oriented around the implant. 
Composites D2VPb were the only composites with capillaries around their entire perimeter, as 
shown in Figure 4.5. 
4.4. Discussion 
Accurate quantification of angiogenesis in the subcutaneous tissue is challenging, and different 
approaches have been applied by research groups depending on each application37-41. For example, 
in studies where ischemia was investigated in large parts of a tissue, the perfusion of the tissue 
(blood volume reaching a specific area) was measured via imaging techniques such as ultra-
sound42, 43. For applications that investigated small tissue areas, such as in the studies reported 
here, histological evaluation is the most common method of assessment of angiogenesis. In the 
current studies, angiogenesis was monitored via immune-staining against sma, which is present on 
the surface of mature blood vessels (vessels with connected venous and arterial branches)44-46. 
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Since the delivery system presented here was developed for implantable biosensors, the area 
nearest to the implant (200 μm from the implant surface) was utilized in counting blood capillaries. 
This quantification approach revealed significant increase in capillary density in the immediate 
vicinity of the implant for composites with the three-TRM combinations. In addition, it is 
important to consider the capillary size and distribution around the implants since these factors 
will affect the total amount of glucose reaching the implant surface and the spatial distribution of 
glucose in the tissue, respectively. Accordingly, low- and high-magnification images of the tissue 
surrounding the implant were analyzed. 
Biosensors rely on analytes (e.g. glucose) to diffuse from the blood to the subcutaneous tissue 
and reach the sensor surface for their functionality. It has been reported previously that concurrent 
release of dexamethasone and VEGF can prevent the FBR and promote angiogenesis over the 
long-term in rats21. In this work, dexamethasone, VEGF and PDGF were delivered simultaneously 
and their relative doses were adjusted to achieve the highest capillary density at minimal distance 
from the implant surface while eliminating interference between the angiogenic and anti-
inflammatory effects of these three TRMs. 
Initially, the dexamethasone dose was kept constant (at the dose previously optimized to 
prevent FBR for implants coated with composites containing only dexamethasone) and the relative 
VEGF and PDGF amounts were varied. It was determined that delivering equal amounts of VEGF 
and PDGF alongside dexamethasone interfered with the anti-FBR effect of the latter, and a fibrotic 
band was observed around the implant (DVP). In addition, no new capillaries developed close to 
the implant; this is probably due to the presence of the fibrotic band obstructing subsequent VEGF 
and PDGF release to the local tissue. It was determined that reducing the amount of PDGF loaded 
in the implants by half (D2VPa) eliminated interference with the anti-FBR effect of 
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dexamethasone, and significant increase in blood vessel density was observed compared to the 
control group (D). 
Based on these results, the VEGF-to-PDGF ratio was kept constant at 2:1, and both growth 
factors were loaded in a single population of microspheres in this ratio (VP_MS). To study the 
extent of the interference between the three TRMs, a higher dexamethasone dose was investigated. 
It was determined that the anti-FBR effect of the implants remained intact, while the capillary 
density was reduced and the average capillary-to-implant distance was increased. This indicates 
that in order to preserve the angiogenic effect of such composites at higher dexamethasone doses, 
the growth factor dose needs to be increased proportionally. 
In the interest of improving biosensor functionality (lag time and sensitivity), it is important to 
note that the formulation that showed maximum angiogenic effect (D2VPb) also had a higher 
capillary density at day 30 compared to the other time points. This variation may potentially affect 
biosensor functionality in terms of stable baseline readings. However, this variation in capillary 
density with time did not occur in formulation 2D2VP (which had a higher dexamethasone dose).  
4.5. Conclusions 
In this work, combinations of dexamethasone, VEGF and PDGF were delivered for the first 
time to prevent FBR and promote angiogenesis. Visual examination of histological images at low 
and high magnifications combined with capillary density measurements around the implants was 
necessary for data interpretation. It was determined that: i) prevention of FBR along with 
maximum angiogenesis around the implants requires all three TRMs in specific relative amounts; 
ii) VEGF has to be administered at higher doses than PDGF; iii) an increase in dexamethasone 
dosing reduces the angiogenic effect of the composites and must be accompanied by a proportional 
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increase in growth factor dosing; and iv) capillary density throughout the implantation period is a 
potential factor that may affect biosensor lag time and sensitivity. 
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Chapter 5 
Continuous Metabolic Monitoring Based on Multi-Analyte Biomarkers to Predict 
Exhaustion 
Abstract 
This work introduces the concept of multi-analyte biomarkers for continuous metabolic 
monitoring. The importance of using more than one marker lies in the ability to obtain a holistic 
understanding of the metabolism. This is showcased for the detection and prediction of exhaustion 
during intense physical exercise. The findings presented here indicate that when glucose and 
lactate changes over time are combined into multi-analyte biomarkers, their monitoring trends are 
more sensitive in the subcutaneous tissue, an implantation-friendly peripheral tissue, compared to 
the blood. This unexpected observation was confirmed in normal as well as type 1 diabetic rats. 
This study was designed to be of direct value to continuous monitoring biosensor research, where 
single analytes are typically monitored. These findings can be implemented in new multi-analyte 
continuous monitoring technologies for more accurate insulin dosing, as well as for exhaustion 
prediction studies based on objective data rather than the subject’s perception.  
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5.1. Introduction 
Metabolic monitoring is the periodic recording of metabolic markers that give information on 
specific metabolic pathways. Diabetes mellitus, obesity and intense physical activity are a few 
examples where close metabolic monitoring is necessary1-3. This is routinely done in a non-
continuous manner, where the individual records their blood glucose, body weight, blood pressure, 
etc. over various periods of time. Technological advances on wearable and/or implantable devices 
have initiated the transition to real-time, continuous monitoring4-8. However, monitoring devices 
have several shortcomings: they trigger the foreign body reaction which results in loss of 
functionality within a few days, they cannot be implanted directly in the bloodstream, and they 
typically record only single analytes. The foreign body reaction to implantable medical devices 
has been shown to be prevented by incorporating drug-eluting biocompatible coatings8-10. When a 
device that is implanted in a peripheral tissue such as subcutaneous tissue is used to monitor analyte 
changes in the blood, loss of sensitivity and lag times are observed11. This is due to the fact that 
analytes have to diffuse from the bloodstream to the interstitial fluid before being detected.  
Exhaustion, also known as fatigue, is the inability of muscle to continue an ongoing physical 
activity12. The perception of exhaustion is highly subjective, and consequently the assessment of 
a subject’s endurance is currently based on semi-empirical observations that link the fitness and 
current state (e.g. heart rate) of each subject with pre-recorded performance levels13,14. However, 
exhaustion has been linked to several metabolic pathways and therefore a close examination of the 
metabolic processes involved in physical activity could facilitate a more accurate prediction of 
exhaustion. Depletion of fuel stored in the muscle (i.e. creatine and glycogen, that are readily 
accessible as an energy source), as well as accumulation of metabolic byproducts (e.g. chloride 
and potassium ions and lactic acid) are considered the causes of exhaustion15,16. These metabolic 
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events take place in the exercising muscle, a body compartment that is not available for real-time, 
continuous monitoring via implantable devices mainly due to the trauma associated with 
intramuscular implantations. 
In this work, exhaustion detection in the subcutaneous tissue using multiple analytes combined 
into multi-analyte biomarkers was investigated. Single-analyte monitoring, such as glucose 
monitoring, creates blind spots in the recorded metabolic state since a single analyte cannot 
account for all pathways involved in a given metabolic event. It is hypothesized that monitoring 
of two analytes (glucose and lactate) will offer a more complete view into metabolic changes 
during exercise that lead up to exhaustion. In the context of exhaustion prediction, glucose and 
lactate are suitable candidates for multi-analyte monitoring: glucose is the primary energy source 
of muscle cells, and lactate is the main by-product of anaerobic metabolism during intense activity.  
To test the above hypothesis, exercise experiments were conducted in normal as well as type 
1 diabetic rats. Diabetic rats were included in the study design since one application of this work 
will be to improve the health of diabetic athletes. External observations (commencement of 
exercise, running speed, and onset of exhaustion) were correlated with internal shifts in 
metabolism (glucose and lactate as single readings or combined into multi-analyte biomarkers) 
recorded in the subcutaneous tissue and the blood. Microdialysis was used to monitor glucose and 
lactate in the subcutaneous tissue and the blood. Microdialysis is a reliable technique that has been 
used extensively in laboratory settings to monitor analyte changes in various tissues.  
5.2. Materials and Methods 
5.2.1. Animal models 
Male Sprague Dawley rats (6 weeks old, 150-170 g) were used as the normal animal model 
(n=6). One group of rats was injected with streptozotocin (60 mg/kg body weight, IP) to induce 
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type 1 diabetes (n=3). Additionally, Zucker Diabetic Fatty (ZDF) rats, an obesity animal model, 
were used in the preliminary studies (n=3). However, data from ZDF rats were not included in this 
manuscript since these animals could not perform intense exercise due to their physical condition. 
All animal studies were done in accordance with the approved guidelines. All studies were 
reviewed and approved by the University of Connecticut’s Institutional Animal Care and Use 
Committee (IACUC) prior to the beginning of the experiments.  
5.2.2. Microdialysis 
Microdialysis was used to monitor analytes in the blood and subcutaneous tissue. Each rat was 
implanted with one microdialysis catheter (20 kDa molecular weight cut-off, CMA Microdialysis 
AB) in the subcutaneous tissue and one in the jugular vein. Catheterization took place with the aid 
of a guiding needle as per the manufacturer’s instructions.  
5.2.3. Exercise experiments 
Rats implanted with two microdialysis catheters were placed in a forced exercise treadmill 
(IITC, Inc.). An isotonic liquid (Ringer’s solution) was pumped through the microdialysis catheters 
at 5 μl/min speed rate (syringe pump, Harvard Apparatus) and samples were collected every 10 
minutes (preliminary studies) and every 6 minutes for the all other studies. After an initial resting 
period to collect baseline data, exercise commenced at maximum running speed. The maximum 
speed varied with each rat and was in the range of 15-17 meters per minute. The onset of 
exhaustion was noted when the rats could not keep up at the maximum pace, and the exercise 
ended when the rats failed to run at all. A recovery period was allowed after the exercise. 
5.2.4. Analyte quantification 
YSI 2300 STAT Plus™ (YSI Life Sciences, Inc.) was used to quantify glucose and lactate 
molar concentrations in the microdialysis samples. Oxygen and carbon dioxide microelectrodes 
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(Microelectrodes, Inc.) were used to determine analyte trends in the microdialysis samples. Since 
oxygen and carbon dioxide monitoring was found unsuitable for this application, only the electrode 
output is reported to obtain the analyte trend. 
5.2.5. Data analysis 
Analyte concentrations were plotted against time as shown in the main text of the manuscript. 
With the exception of the exhaustion prediction times (which are reported as average values ± 
standard deviation), animal data could not be aggregated for statistical analysis due to variability 
on the fitness and endurance level of each rat. Representative plots of analyte trends are shown to 
showcase the feasibility of multi-analyte biomarkers for exhaustion prediction.  
5.3. Results 
5.3.1. Choice of analytes to be monitored 
Glucose and lactate were chosen as markers based on preliminary studies where blood and 
subcutaneous glucose, lactate, oxygen and carbon dioxide were monitored in healthy and obese 
animals during light exercise. The results indicated that oxygen and carbon dioxide are not suitable 
analytes for predicting exhaustion. As shown in Figure 5.1, oxygen trends did not respond to light 
exercise while carbon dioxide values were highly unstable. 
5.3.2. Glucose and lactate changes during intense exercise 
Figure 5.2a depicts a representative metabolic profile for a healthy rat. Glucose and lactate 
changes in the blood and subcutaneous tissue are shown in four zones. A: prior to exercise (baseline 
measurements); B: during intense exercise; C: during light exercise (post-exhaustion); and D: 
recovery. Since glucose and lactate have to diffuse from the blood to the subcutaneous tissue to be 
taken up by the microdialysis catheter, the small differences in blood and subcutaneous values 
were expected. A spike in both glucose and lactate levels in the blood as well as the subcutaneous 
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tissue are observed upon commencement of exercise, a typical observation when transitioning 
from rest to activity. Exhaustion was first observed 57 minutes into the exercise, when the animal 
could not keep up and the treadmill speed had to be adjusted. Full exhaustion was observed 30 
minutes later, when the animal was unable to continue the exercise. Interestingly, glucose and 
lactate showed a trend change around 45 minutes into the exercise, 12 minutes before the first 
physical evidence of exhaustion and 42 minutes before full exhaustion (indicated by red ovals). 
The exhaustion-prediction window varied from 12 to 20 minutes among the rats, due to varied 
endurance levels. The average exhaustion prediction time was 16.17 ± 4.16 min. 
Similar observations of exhaustion prediction were made in untreated, type 1 diabetic rats 
(Figure 5.2b) with an average exhaustion prediction time of 8.60 ± 3.08 min. However, diabetic 
rats did not show a gradual manifestation of exhaustion, but reached full exhaustion immediately. 
As shown in Figure 5.2b, glucose as well as lactate build-up was observed. The type 1 diabetic 
rats were untreated (they did not receive insulin injections). As a result, glucose released from the 
liver as an energy source could not be internalized by muscle cells which failed to perform the 
exercise shortly after glucose and lactate build-up stopped. It should be noted that the data from 
diabetic rats exhibited one anomaly: the glucose values obtained from the microdialysis samples 
were consistently lower than the values obtained from normal rats. This conflicted with glucose 
values obtained via tail vein pricking to confirm the diabetic state (>350 mg/dL). However, the 
interpretation of the data shown here relies on the trend rather than the absolute values of glucose 
and lactate, and this anomaly did not interfere with data interpretation. 
The findings described above confirmed our hypothesis that detectable metabolic changes 
precede physical manifestations of exhaustion. Accordingly, these changes may be used as a 
predictive tool for exercise endurance and exhaustion. 
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5.3.3. Multi-analyte biomarker identification  
The observations described above are based on blood levels of glucose and lactate (monitored 
independently) as these changes were not as evident in the subcutaneous tissue. This poses a 
potential problem in translating these findings into subcutaneously-implantable monitoring 
platforms. It was hypothesized that by combining glucose and lactate readings into multi-analyte 
biomarkers it may be possible to increase the monitoring resolution in the subcutaneous tissue 
since glucose and lactate account for aerobic and anaerobic metabolism, respectively. Glucose 
(GLU) and lactate (LAC) combinations were investigated. Since one glucose molecule yields two 
lactate molecules, the lactate concentration was used directly or multiplied by two to account for 
this. The efficacy of the biomarkers to increase the monitoring resolution in the subcutaneous 
tissue was tested by measuring the absolute slope changes during two metabolic events: rest-to-
activity transition (first peak in Figures 5.2a and 5.2b) and pre-exhaustion trend changes (second 
peak in Figures 5.2a and 5.2b). It was determined that combinations of biomarkers were several 
times more sensitive to metabolic changes in the subcutaneous tissue compared to the blood as 
shown in Figure 3a for normal rats and Figure 3b for diabetic rats. Single analyte changes relative 
to the baseline measurements (%CLU and %LAC) also showed higher sensitivity in the 
subcutaneous tissue than the blood. The utilization of percent changes of single analytes is not 
feasible for continuous monitoring systems as stable baseline measurements are not usually 
available outside controlled laboratory environments. This is especially relevant for individuals 
undergoing fitness level changes (due to training or disease management) whose metabolic 
baseline is continuously shifting, as well as subjects with no control over their activity levels such 
as deployed military personnel.  
5.3.4. Multi-analyte biomarkers for prediction of exhaustion 
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Based on the results shown in Figures 5.3a and 5.3b, 2LAC/GLU was plotted vs. time for 
normal and diabetic rats (Figure 5.4a). As shown in this figure, 2LAC/GLU can be used to predict 
exhaustion with more accuracy in the subcutaneous tissue than the blood. 3D surface plots of 
glucose, lactate, and time were constructed (Figure 5.4b). These plots incorporate all possible 
combinations of glucose and lactate and when implemented into standardized exercise routines17-
27 can provide feedback on the fitness and endurance of the subject. As shown in Figure 5.4b, the 
exhaustion-predictive metabolic changes described above in response to exercise are more 
profound in areas where glucose and lactate are combined compared to the peripheral regions of 
the graph where glucose and lactate are plotted separately. 
Discussion 
This work explored the potential of the subcutaneous tissue, a device implantation-friendly 
space, to be used in continuous metabolic monitoring for exhaustion prediction. The ultimate goal 
is to utilize the proof-of-concept presented here to develop exhaustion-predicting algorithms that 
rely on holistic metabolic shifts instead of single markers such as heart rate or lactate. An array of 
biomarkers that can be used in such algorithms was successfully identified, and furthermore the 
concept of constructing 3D biomarker plots was presented. 
Continuous monitoring of more than one analyte can reveal the interdependence of different 
metabolic pathways and the metabolic flexibility of the individual (the ability to switch from 
aerobic to anaerobic utilization of energy and vice versa). Our findings revealed that multi-analyte 
biomarkers based on glucose and lactate are far more responsive in the subcutaneous tissue (an 
implantation-friendly compartment) than in the blood. This is a significant breakthrough for 
subcutaneously-implanted monitoring devices since until now their inability to detect analytes 
directly in the blood was considered a handicap.  
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The size and shape of the semi-implantable microdialysis probe makes it a good model for 
implantable biosensors. In the future, when implantable multi-sensors become available, the 
concept of continuous multi-analyte monitoring for exhaustion prediction presented here will be 
applied to individualized algorithms paired with such devices. The applications of this concept are 
many. Long-term changes in multi-analyte biomarker interdependence are expected to reveal 
progress in the training of athletes, management of diabetic patients, development of pre-diabetes 
in obese subjects, etc. Here it was shown that multi-analyte biomarkers can be used to predict 
exhaustion, which is crucial for diabetic athletes, deployed military personnel, and other high-risk 
individuals involved in intense physical activity. 
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Chapter 6 
Conclusions and Future Studies 
6.1. Summary and conclusions 
There are currently a number of semi-implantable biosensors on the market that monitor 
glucose continuously; these devices, however, lose functionality after 6-10 days due to the tissue 
reaction to the implanted (needle-like) portion of the device. As a result, to this day, continuous 
glucose monitoring has not been implemented into routine diabetes management. Consequently, 
there is a great need for a biosensor that i) functions for prolonged periods of time and ii) has 
minimal interference with the daily life of diabetic patients to enable patient compliance. Such a 
biosensor will revolutionize diabetes management with additional applicability in the fields of 
exercise metabolism as well as remote health monitoring in the military. 
To achieve long-term sensor functionality in vivo, modification of the tissue reaction to 
implanted biosensors is necessary. A significant amount of research has led to the realization of 
biosensor coatings that prevent the FBR and prolong sensor lifetime in vivo. These coatings had 
previously been tested in small animal models (normal and diabetic rats). Accordingly, the main 
scope of this work was to transfer the technology from small to large animals, expand the coating 
functionality to promote angiogenesis alongside prevention of FBR, and explore applications of 
sensors in exercise physiology. 
Key differences in the FBR to subcutaneous implants between a small (rat) and large (minipig) 
animal model were identified for the first time. The onset and severity of fibrosis was determined 
to be a significant difference, with minipigs demonstrating earlier onset and more severe chronic 
inflammation compared to rats. It was determined that dexamethasone release from the implant 
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coatings must be tailored to the species-specific stages of the FBR. In order to counter the more 
severe chronic inflammation observed in minipigs compared to rats, dexamethasone release must 
be continuous, with no lag phase. The effective dexamethasone dosing regime was 100 μg during 
the first day and 10 μg/day thereafter; this regime is applicable to implants of similar size (7 x 0.15 
mm) and can be extrapolated to longer implantation periods in minipigs. These findings can 
facilitate the dose calculations in the first-in-human studies as porcine skin is the optimal animal 
model for dermal formulations. 
The species differences that were identified in the first part of this work were utilized to 
develop a novel method for the preparation of microspheres containing insoluble drugs with 
homogeneous drug distribution, high loading and low burst release. Dexamethasone microspheres 
prepared by this method, together with crystalline dexamethasone, were incorporated in 
microsphere/hydrogel composite coatings to achieve an approximately 40% burst release followed 
by a constant drug release pattern with no lag phase. This microsphere/hydrogel composite coating 
formulation successfully prevented FBR in a large animal model for a period of one month via 
localized release of low doses of dexamethasone (approximately 10 μg per day, which is close to 
1000 times below the level that would result in any systemic effects (0.75 to 9 mg per day). This 
is the first time that such low doses of dexamethasone, suitable for miniaturized medical devices 
such as biosensors, have been used to prevent FBR in a large animal model. 
In order to expand the effects of the composite coatings, combinations of dexamethasone, 
VEGF and PDGF were delivered for the first time to prevent FBR and promote angiogenesis in a 
rat model. Visual examination of histological images at low and high magnifications combined 
with capillary density measurements around the implants was necessary for data interpretation. It 
was determined that: i) prevention of FBR along with maximum angiogenesis around the implants 
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requires all three TRMs in specific relative amounts; ii) VEGF has to be administered at higher 
doses than PDGF; iii) an increase in dexamethasone dosing reduces the angiogenic effect of the 
composites and must be accompanied by a proportional increase in growth factor dosing; and iv) 
capillary density throughout the implantation period is a potential factor that may affect biosensor 
lag time and sensitivity. 
Lastly, this work explored the potential of the subcutaneous tissue, a device implantation-
friendly space, to be used in continuous metabolic monitoring for exhaustion prediction. The 
ultimate goal is to utilize the proof-of-concept presented here to develop exhaustion-predicting 
algorithms that rely on holistic metabolic shifts instead of single markers such as heart rate or 
lactate. An array of biomarkers that will be used in such algorithms was successfully identified, 
and furthermore the concept of constructing 3D biomarker plots was presented. It was determined 
that physical exhaustion is preceded by metabolic changes that can be picked up via continuous 
monitoring of glucose and lactate in the subcutaneous tissue, indicating that prediction of 
exhaustion with an approximately 14-minute window is possible. This will be of paramount 
importance for deployed soldiers, diabetic athletes and other high-risk individuals involved in 
intense physical activity. 
The significant and novel contributions resulting from this work include: i) identification of 
key species differences between the FBR in small and large animals; ii) development of a novel 
dexamethasone-loaded microsphere fabrication method to accommodate the identified species 
differences; iii) prevention of the FBR in a large animal model using small amounts of anti-
inflammatory drug release; iv) development of a innovative, single-vessel protein microsphere 
preparation method with enhanced efficiency, product recovery, and sterility; v) application of 
osmosis to encapsulate proteins in polymer microspheres; vi) delivery of dexamethasone, VEGF, 
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and PDGF to prevent FBR while promoting angiogenesis in a rat model; vii) adjustment of the 
three TRM dose ratios to eliminate interference in their respective actions; ix) application of 
continuous, multi-analyte monitoring to predict exhaustion in normal and diabetic rats; and x) 
introduction of multi-analyte biomarkers for metabolic monitoring in the subcutaneous tissue with 
higher sensitivity than the blood. 
The above contributions will advance the field of metabolic monitoring via implantable 
biosensors by transferring the technology in large animals for pre-clinical testing, expanding the 
sensor lifetime to three months with the use of angiogenic growth factors, and identifying 
important biomarkers that can be incorporated in metabolic monitoring algorithms. 
6.2. Future studies 
The novel microsphere fabrication methods developed here (dexamethasone-loaded and 
protein-loaded presented in Chapters 3 and 4, respectively) have been successfully tested in vivo. 
Different drugs (small and large molecules) can be encapsulated with these methods to expand the 
potential applications of these microspheres. For example, the osmosis-driven microsphere 
preparation method can be modified to include both small and large molecules, whereas the drug-
polymer co-precipitation method can be further investigated for longer drug release periods. 
So far, the electrochemical elements of the sensors were optimized based on testing in small 
animals. The biosensor coatings developed and used here to prevent FBR in large animals can be 
used in large animal sensor testing. Such testing is necessary in order to transition to the first-in-
human studies of coated implantable biosensors. 
It was demonstrated here that adjustment of dexamethasone, VEGF, and PDGF dose ratios 
eliminate their interference for one month implantation periods. This effect may be studied for 
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longer periods, such as three and six months. It is expected that the ratio that works for one month 
will be effective for longer periods as well, however, this needs to be confirmed via careful 
examination of longer-releasing formulations. In addition, composites that release dexamethasone, 
VEGF, and PDGF have not been used in sensor testing studies. The effect of the capillary density 
as well as the capillary distance from the sensor surface has to be studied against sensor 
functionality in the long-term. 
The importance of multi-analyte monitoring for exhaustion prediction has been demonstrated 
here. The next step will translate the ability of such biomarkers to predict exhaustion into 
algorithms that can be incorporated in biosensors. Rigorous validation of such algorithms in 
normal as well as diabetic animals will pave the way for human studies. In addition, multi-analyte 
monitoring may be applied to study other metabolic diseases such as obesity. 
 
 
 
67 
 
Appendix I – Figures 
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Figure 2.1. Histological evaluation of the foreign body reaction to control (no dexamethasone) 
implants. Star denotes implant location. Connective tissue is stained pink, collagen fibers light 
pink and inflammatory cells purple (H&E staining). a: day 1; b: day 3; c: day 7; d: day 14; e: day 
21; f: day 30 post-implantation (n=3). Scale bar: 500 μm. 
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Figure 2.2. Comparison of FBR in rats and minipigs 7 days post-implantation. Star denotes 
implant location. Connective tissue is stained pink, collagen fibers light pink and inflammatory 
cells purple (H&E staining). Green arrow: collagen fibers; black arrow: fibroblasts. Rat image 
taken from Patil et. al.43 Fibroblasts were identified based on the cell morphology. Active 
fibroblasts have oval shape with spherical nucleus and are characteristically positioned in-between 
collagen fibers which they produce. 
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Figure 2.3. Histological evaluation of the foreign body reaction to dexamethasone-releasing 
implants R, R9, R11 and R150 on days 3, 7, 14, 21, and 30 post-implantation. Star denotes implant 
location. Connective tissue is stained pink, collagen fibers light pink and inflammatory cells purple 
(H&E staining) (n=3). Scale bar: 500 μm. 
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Figure 2.4. Histological evaluation of the foreign body reaction to dexamethasone-releasing 
implants R2W. Star denotes implant location. Connective tissue is stained pink, collagen fibers 
light pink and inflammatory cells purple (H&E staining). a: day 1; b: day 3; c: day 7; d: day 11; e: 
day 14; f: day 21 post-implantation (n=4). Scale bar: 500 μm. 
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Figure 3.1. Polarized light microscopy (PLM) images of two emulsions during PLGA microsphere 
preparation. Drug crystals appear as bright spots in the PLM images. (a) Example of non-
optimized process, with dexamethasone crystals formed outside the polymer phase (polymer 
droplets not visible due to their inability to polarize light). (b) Optimized formulation with 
dexamethasone precipitated inside the polymer phase. Magnification: 10X, scale bar: 500 μm. 
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Figure 3.2. PLM images of negative control formulation (left) with poor drug distribution in the 
polymer matrix and optimized formulation (right). Dexamethasone crystals appear bright under 
PLM while the polymer is transparent. Magnification: 40X, scale bars: 10 μm. 
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Figure 3.3. Cumulative in vitro release of dexamethasone from optimized PLGA microspheres 
embedded in a PVA hydrogels. All values are average ± SD (n = 3). Linear regression was applied 
from day 4 to day 45. 
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Figure 3.4. Histological evaluation of the foreign body reaction to control (no dexamethasone) 
implants. Star denotes implant location. Connective tissue is stained pink, collagen fibers light 
pink and inflammatory cells purple (H&E staining). (a) day 3; (b) day 7; (c) day 14; (d) day 21; 
(e) day 30 post-implantation. Magnification: 10X, scale bar: 500 μm. 
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Figure 3.5. Histological evaluation of the foreign body reaction to coated silicon chips with the 
optimized PLGA microsphere formulation. Star denotes implant location. Connective tissue is 
stained pink, collagen fibers light pink and inflammatory cells purple (H&E staining). (a) day 3; 
(b) day 7; (c) day 14; (d) day 21; (e) day 30 post-implantation. Magnification: 10X, scale bar: 500 
μm. 
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Figure 3.6. Histological evaluation of FBR to composites with the optimized PLGA microsphere 
formulation with no silicon chips at their core. Star denotes implant location. Connective tissue is 
stained pink, collagen fibers light pink and inflammatory cells purple (H&E staining). (a) day 3; 
(b) day 7; (c) day 14; (d) day 21; (e) day 30 post-implantation. Magnification: 10X, scale bar: 500 
μm. 
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Figure 4.1. Schematic representation of the single-vessel microsphere preparation process. 
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Figure 4.2. a) Confocal microscopy images of protein microsphere formulations with (right) and 
without (left) NaCl in the outer water phase; b) drug loading, encapsulation efficiency, and % burst 
release of the formulations with and without NaCl (mean ± SD, n=3). 
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Figure 4.3. Anti-sma-stained tissue sections showing normal tissue (N) and composites C, D, DV, 
DVP, and D2VPa. Star denotes implant location. Magnification: 20x. Scale bar: 150 μm. 
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Figure 4.4. H&E-stained tissue sections of composites D, DV, D2VPb, and 2D2VP at different 
time points following implantation. Star denotes implant location. Magnification: 10x. Scale bar: 
500 μm. 
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Figure 4.5. Anti-sma-stained tissue sections of composites D, DV, D2VPb, and 2D2VP at 
different time points following implantation. Star denotes implant location. Magnification: 10x. 
Scale bar: 500 μm. 
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Figure 4.6. Anti-sma-stained tissue sections of composites D, DV, D2VPb, and 2D2VP at 
different time points following implantation. Star denotes implant location. Magnification: 140x. 
Scale bar: 100 μm. 
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Figure 4.7. Capillary density within a 200 μm distance from the implant surface for composites 
D, DV, D2VPb and 2D2VP (mean ± SD, n=3).  
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Figure 5.1. Effect of light and intense exercise on oxygen and carbon dioxide levels in the blood 
and subcutaneous tissue. Areas shaded blue and green indicate light and intense exercise, 
respectively, and unshaded areas indicate periods of inactivity (rest or recovery). The top panel 
displays oxygen level changes and the bottom panel carbon dioxide changes in the dialysate. 
Arrows indicate y axis. Oxygen levels did not respond to light exercise but only during intense 
exercise. Carbon dioxide levels responded to both light and intense exercise, but showed highly 
unstable readings. 
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Figure 5.2. Effect of intense exercise and exhaustion on glucose and lactate levels in the blood 
and subcutaneous tissue. Areas shaded green and red indicate periods of intense exercise and 
exhaustion, respectively. Exhaustion was defined as the time when the animal could not keep up 
with the exercise and the running speed needed to be adjusted. Unshaded areas indicate periods of 
inactivity (rest or recovery). Arrows indicate y axis. Top panels show glucose and lower panels 
show lactate changes in the dialysate. Panel a shows representative graph from a normal rat and 
panel b from a diabetic rat. Changes in analyte trends precede the onset of exhaustion (red ovals). 
These are clearer in lactate trends for both normal and diabetic rats. 
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Figure 5.3. Slope changes for various biomarker combinations of glucose (GLU) and lactate 
(LAC). All ratios are molar and the percentile changes are calculated based on the baseline 
measurements before the commencement of the exercise. The first peak represents metabolic 
changes from rest to activity and the second peak metabolic changes that precede exhaustion 
(predictive). Panel a shows representative results from a normal rat and panel b from a diabetic 
rat. 
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Figure 5.4a. Effect of intense exercise and exhaustion on the biomarker 2LAC/GLU (molar ratio 
of lactate and glucose multiplied by 2). Areas shaded green and red indicate periods of intense 
exercise and exhaustion, respectively. Exhaustion was defined as the time when the animal could 
not keep up with the exercise and the running speed needed to be adjusted. Unshaded areas indicate 
periods of inactivity (rest or recovery). Arrows indicate y axis. Red ovals indicate the exhaustion-
prediction point. The top panel shows representative results from a normal rat and the bottom panel 
from a diabetic rat. 2LAC/GLU is the optimum biomarker for detecting metabolic changes in the 
subcutaneous tissue predictive of imminent exhaustion. The results are less clear in the diabetic 
rat; please note that diabetic rats did not receive insulin treatment, and the baseline glucose was 
high. This likely interfered with the biomarkers. 
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Figure 5.4b. 3D representation of glucose and lactate changes during intense exercise and 
exhaustion in a normal rat. This plot reveals the interdependence of glucose and lactate that can be 
extrapolated to evaluate the metabolic flexibility (the ability to transition from aerobic to anaerobic 
energy utilization). The peak in the graph indicates metabolic changes predictive of exhaustion.  
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Appendix II – Tables 
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Table 2.1. Implant composition and size. 
Implant Microspheres PLGA per ml PVA 
solution (mg) 
Length 
(mm) 
Control Blank 75 7 
R 1M 75 7 
R150 1M 150 7 
R9 1M 75 9 
R11 1M 75 11 
R2W 2W 150 7 
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Table 2.2. Physical properties of PLGA microspheres. Results are average values ± SD (n=3). 
Microspheres 
Extend of 
polymer 
degradation 
PLGA MW 
(g/mol) 
Mean particle 
size (um ± SD) 
Drug loading 
(% w/w ± SD) 
1M 1 month 25,000 49.18 ± 5.84 10.54 ± 0.34 
2W 2 weeks 12,000 38.95 ± 1.94 11.86 ± 0.13 
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Table 4.1. Microsphere content in the composites 
Composite 
Microspheres (mg) 
per ml PVA solution 
D_MS V_MS P_MS VP_MS 
C - - - - 
D 75 - - - 
DV 75 50 - - 
DVP 75 50 50 - 
DV2P 75 25 50 - 
D2VPa 75 50 25 - 
D2VPb 75 - - 50 
2DVP 100 - - 50 
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Table 4.2. Microsphere characterization 
Formulation Drug Loading Particle Size 
(μm) Dexamethasone 
(% w/w) 
VEGF 
(ng/mg) 
PDGF 
(ng/mg) 
D_MS 10.54 ± 0.34 - - 39.63 ± 5.44 
V_MS - 3.19 ± 0.37 - 33.07 ± 5.46 
P_MS - - 3.86 ± 0.22 41.69 ± 7.80 
VP_MS - 3.32 ± 0.17 1.91 ± 0.16 38.37 ± 4.46 
 
